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ABSTRACT
Brookelyn J. Haddock
The Role of MARCKS in Mast Cell Regulated Exocytosis
Under the Supervision of C. William Davis
MARCKS is implicated as a critical regulator of regulated exocytosis. We studied the 
role of MARCKS in mast cell regulated exocytosis by comparing the secretion of embryonic 
hepatic-derived WT and MARCKS-deficient mast cells. Mast cells in suspension showed no 
secretory differences, however, adherent MARCKS-deficient cells demonstrated enhanced se-
cretion and accelerated release of secretory cargo compared to WT. Surprisingly, application 
of purported MARCKS inhibitory peptides showed no MARCKS-specific inhibition. Thus, 
while MARCKS is not essential for mast cell regulated exocytosis, it does negatively modulate 
secretion.
In a separate study, conserved regions of MARCKS were tested for their necessity in 
the subcellular targeting of MARCKS from the PM to the cytosol, believed to be crucial for 
its multiple functions. We confirmed this movement using live cell imaging of HEK293 cells 
transfected with full-length MARCKS constructs. Notably, phosphorylated MARCKS associ-
ated with cytosolic membranes, and only myristoylation and PKC phosphorylation affected the 
translocation process. 
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Significance of Regulated Exocytosis 
Exocytosis, one of the cellular events separating eukaryotes from prokaryotes, is used 
to insert proteins into the plasma membrane (PM) and to release materials, including signaling 
molecules, to the extracellular environment. Exocytic secretion is commonly divided into con-
stitutive and regulated pathways, the former being responsible for protein insertion and tonic 
secretion, while the latter generally relates to neurotransmission, and exocrine, endocrine, para-
crine and autocrine secretion. Constitutive exocytosis does not require receptor activation and 
its rate of release is limited only by the rate of cargo synthesis. In contrast, regulated exocytosis 
requires receptor activation, and cargo, packaged into secretory vesicles or granules (SGs), 
and is held in a reserve pool until an extracellular ligand activates the pathway. This regulated 
exocytic pathway is generally found in specialized secretory cells and it regulates many as-
pects of physiology, host defense (Sanchez-Mejorada & Rosales, 1998; Watanabe, et al., 1999; 
Baumann, et al., 2001; Burley, et al., 2007; Davis & Dickey, 2008) and synaptic neurotrans-
mission (Li, et al., 2005; Jacques & Abdel-Samad, 2007).
Regulated exocytosis of mucins from goblet cells in a healthy respiratory system is a 
crucial part of mucociliary clearance, a host defense mechanism enabling the airways to clear 
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Fig. 1.1:  The regulated exocytic pathway of secretory cells
 Based on the actin barrier hypothesis, resting cells have a meshwork of actin filaments serving 
as a barrier and negatively regulating secretion by inhibiting SG access to docking sites on the 
PM. After stimulation, a signal transduction pathway activates numerous second messengers 
resulting in destabilization of the actin barrier and release of intracellular calcium stores. Fol-
lowing disruption of the actin barrier, by unknown mechanism, SGs dock with exocytic fusion 
sites on the PM and are primed for membrane fusion and cargo exocytosis via SNARE-medi-
ated mechanisms. A localized calcium signal is required for the final exocytic event.
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away inhaled contaminants and bacteria and preventing infection. Mucins maturate to form 
mucus, which is transported along the luminal surface of the airway epithelium by rhythmi-
cally beating cilia on ciliated cells to clear particulates and pathogens from the lungs. Mul-
tiple respiratory disorders, such as cystic fibrosis (CF) and primary ciliary dyskinesia (PCD), 
despite having different pathologies, suffer from excessive mucin secretion in the upper air-
ways and lungs through involvement of the inflammation response (Davis & Dickey, 2008). 
This aberrant secretion, combined with inability to remove pathogens from the lungs, leads 
to clogged airways, accumulated immune cells, and dry, viscous mucus, eventually resulting 
in asphyxiation. If mucin secretion could be inhibited in lung pathologies, patient morbidity 
could be significantly reduced.
However, excessive mucin secretion is not the only regulated exocytic pathway con-
tributing to respiratory diseases. Asthma and chronic obstructive pulmonary disorder (COPD) 
are characterized by inflammation due to hypersensitivity of immune cells inducing broncho-
constriction. Mast cells are critical secretory immune cells recognized to be involved in this 
process (Bradding, et al., 2006; Gonzalo, et al., 2007; Kalin, et al., 2008; Ryzhov, et al., 2008). 
Significantly, mast cells initiate the inflammatory response by utilizing regulated exocytosis 
to release pro-inflammatory and chemotactic mediators to activate and recruit other immune 
cells. Levels of these released products, due to increased regulated exocytosis or an increased 
number of mast cells, are typically increased compared to non-pathological conditions and 
can initiate a more severe inflammatory reponse to the same amount of stimuli (Bradding, et 
al., 2006; Gonzalo, et al., 2007; Ryzhov, et al., 2008). For example, one chemokine product 
released from mast cells that functions as a trigger of pulmonary inflammation response, in-
cluding mucus hypersecretion, was found to be increased five-fold in asthmatics (Gonzalo, 
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et al., 2007). These studies demonstrate that regulated exocytosis from mast cells alone can 
potentiate respiratory disorders, along with other types of secretory cells involved in the respi-
ratory system. Consequently, understanding the regulatory aspects of regulated exocytosis may 
provide potential therapeutic targets in numerous cell types for many disorders; in this study, 
we focus on the potential role of the MARCKS protein in exocytic secretion. 
Mechanisms of Regulated Exocytosis
Though sharing similar components, secretory cells undergoing regulated exocytosis 
can be subdivided into numerous categories. One division is between neuronal and non-neuro-
nal secretion. Neuronal secretion is stimulated by an action potential, resulting in an immediate 
influx of calcium. Resting neuronal cells contain a readily releasable pool of secretory vesi-
cles partially bound to the PM, so vesicle exocytosis occurs in milliseconds (Carr & Munson, 
2007). In contrast, the larger vesicles of non-neuronal cells are distant from and unbound to 
the PM prior to receptor activation. These SGs must not only fuse with the PM to release their 
cargo, like neuronal cells, but in addition they must first migrate to and dock with the PM. Due 
to these additional steps, regulated exocytosis in non-neuronal cells takes place in seconds to 
minutes, even though exocytic fusion, per se, occurs in the millisecond time frame. Regulated 
exocytic pathways can also be divided between excitable cells and secretory cells. Excitable 
cells are activated by calcium influx through V-gated channels, while secretory cells are acti-
vated by receptor-mediated processes that generally trigger a mobilization of intracellular cal-
cium (Ca2+). Notably, some secretory cells, such as chromaffin cells, are also excitable cells. 
Mast cells, utilized in these studies, are non-neuronal, secretory cells, and undergo the type of 
regulated exocytosis depicted in Fig. 1.1.
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In resting secretory cells, a meshwork of cortical actin filaments lies between the PM 
and intracellular SGs that functions as a barrier to prevent contact (Bader, et al., 2004; Mala-
combe, et al., 2006). Upon receptor activation, a signaling cascade is initiated, including ac-
tivation of protein kinase C (PKC), which results in disruption of the barrier (Trifaro, et al., 
2002; Peng & Beaven, 2005; Davis & Dickey, 2008). This disruption, hypothesized to be 
mediated by MARCKS and/or scinderin (Vitale, et al., 1991; Trifaro, et al., 2002; Eitzen, 
2003; Pene, et al., 2005), allows SGs to dock on the PM. Like all regulated exocytic pathways, 
the SG binding to the PM, and membrane fusion steps that follow are mediated by SNARE 
[soluble NSF (N-ethylaleimide-sensitive fusion protein) adaptor protein receptor] proteins. 
SNAREs are localized to the cytoplasmic surface of both vesicles and the PM. Vesicle-asso-
ciated SNARES (v-SNARES) include VAMPs, a large protein family, while PM-associated 
SNARES (t-SNARES) include the SNAP 23/25 family of proteins and Syntaxin. When v-
SNARES and t-SNARES come into contact and assemble, they form a stable complex made up 
of a quadruple α-helix, a process termed priming. Upon a suitable, generally localized calcium 
signal, the SNARE complex undergoes a calcium-mediated conformational change that coils 
the helical structure and releases the energy necessary for fusion between the two membranes. 
SNARE assembly, priming, and mediation of membrane fusion is a highly regulated process 
controlled by multiple proteins, including members of the Munc 18 and Munc 13 families, 
complexins, and synaptotagmins. Once membrane fusion occurs, the SNARE complex forms 
a fusion pore, through which the contents of the SG are released into the extracellular environ-
ment (Rizo, et al., 2006; Davis & Dickey, 2008; Melicoff, et al., 2009). Additionally, a recent 
re-examination of evidence has suggested that actin cytoskeletal remodeling, believed crucial 
for initial cortical actin disruption and SG trafficking and docking, may also be a critical regu-
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lator of membrane fusion and pore formation (Bader, et al., 2004; Malacombe, et al., 2006). 
The different mechanisms and regulators involved in regulated exocytosis at each point 
of the pathway are understood to varying degrees. The portions of regulated exocytosis shared 
by non-neuronal and neuronal cells, specifically the SNARE-mediated mechanisms and regu-
lation of docking, priming and membrane fusion, have been relatively well characterized. In 
comparison, much less has been elucidated about the disparate portions of regulated exocy-
tosis: namely, the mechanisms and regulators responsible for the actin barrier disruption, SG 
trafficking and SG docking that occur after secretory cell activation. An important regulatory 
role for actin remodeling in regulated exocytosis has been ascribed to MARCKS (Trifaro, et 
al., 2000; Trifaro, et al., 2002; Eitzen, 2003). We have focused on this hypothesis, taking ad-
vantage of an available gene-interrupted mouse model (Stumpo, et al., 1995; Swierczynski, et 
al., 1996).
Myristoylated Alanine Rich C Kinase Substrate (MARCKS) Gene Family
MARCKS is a ubiquitously expressed PKC substrate previously demonstrated to regu-
late actin cytoskeleton dynamics in numerous cell processes (Myat, et al., 1997; Disatnik, et 
al., 2004; Finlayson & Freeman, 2009; Eckert, et al., 2010). MARCKS and its only other fam-
ily member, MARCKS-related protein (MRP), have three conserved domains: an N-terminal 
consensus sequence site for myristoyl modification, a MARCKS homology domain 2 (MH2) 
of unknown function, and a phosphorylation site domain (PSD) containing the serine residues 
phosphorylated by PKC (Stumpo, et al., 1989; Aderem, 1992) (Fig. 1.2). The PSD is also a 
highly basic region implicated in actin (Yarmola, et al., 2001), calmodulin (Aderem, 1992; 
Aderem, 1995; Qin & Cafiso, 1996) and phosphatidylinositol 4,5-bisphosphate (PIP2) (Wang, 
7
Fig. 1.2:  Conserved Regions of MARCKS Sequence. The two-member MARCKS gene 
family has three regions of highly conserved sequence. The first is a co-translational myristoyl 
consensus sequence site. The second is the MH2 domain of unknown function. The third re-
gion is the PSD domain where the serines phosphorylated by PKC are located. Additionally, 
an N-terminal sequence is shown, which has been implicated in MARCKS targeting, though 
not formally identified as a domain.
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et al., 2001; Wang, et al., 2002) binding to membranes. Structurally, MARCKS is a natively 
unfolded protein that binds to the cytosolic leaflet of the PM in resting cells (Qin & Cafiso, 
1996; Tzlil, et al., 2008). PKC phosphorylation electrostatically neutralizes the PSD of both 
MARCKS and MRP, and causes translocation from the plasma membrane (PM) to the cytosol, 
a movement hypothesized to be crucial to the function of these two cytoskeletal-associated 
proteins (Ohmori, et al., 2000; Disatnik, et al., 2004; van den Bout, et al., 2007; Tzlil, et al., 
2008). 
Other than a clear understanding of MARCKS/MRP activation and translocation, how-
ever, the exact function and mechanism of the MARCKS family proteins has not yet been fully 
elucidated. Functions in cell attachment, cell spreading, (Myat, et al., 1997; Disatnik, et al., 
2004; Eckert, et al., 2010) integrin-associated signaling, (Vuori & Ruoslahti, 1993) phagocy-
tosis, (Zhu, et al., 1995; Carballo, et al., 2009) and regulated exocytosis (Elzagallaai, et al., 
2000; Rose, et al., 2001; Jerdeva, et al., 2005; Li, et al., 2005; Eliyahu, et al., 2005; Eliyahu, et 
al., 2006; Park, et al., 2006; Andreas, et al., 2009) have all been suggested for the MARCKS 
gene family.
MARCKS and Immune Challenge
MARCKS and MRP are regulated spatially, developmentally, and in response to im-
mune challenge (Rose, et al., 1996; Yokoyama, et al., 1998; Chun, et al., 2009). Neutrophils 
primed for inflammatory responses by pretreatment with inflammatory mediators, tumour 
necrosis factor alpha (TNF-α) or lipopolysacchharide (LPS), demonstrated increased protein 
synthesis of MARCKS (Thelen, et al., 1990). In a macrophage cell line activated by LPS, 
MRP transcription levels were also increased (Chang, et al., 1999). A recent study suggests 
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this upregulation of MRP and MARCKS is related to chemotactic transmigration of these 
activated macrophages (Chun, et al., 2009), while others suggest it is involved with macro-
phage phagocytosis and cell spreading (Zhu, Bao, Li, 1995; Underhill, et al., 1998; Zhou & 
Li, 2000). In another cell type, murine microglia, when activated by LPS to transform them to 
phagocytic macrophage-like immune cells, significantly increased protein levels of MARCKS 
and MRP (Rose, et al., 1996). Pretreatment of isolated human neutrophils with the MARCKS-
NH2 terminus (MANS) peptide was correlated to decreased F-actin amounts and inhibition of 
both their migration upon immune activation and b2 integrin-mediated adhesion (Eckert, et 
al., 2010). Conclusions about which function MARCKS and MRP serve when they are up-
regulated in response to inflammatory challenge remain disparate due to the fact that studies 
of cells derived from MRP or MARCKS-deficient mouse models do not always agree with 
overexpression, peptide, and knockdown studies. In the absence of a complete knockdown of 
the MARCKS family members, there is always the possibility of non-physiological effects due 
to abnormally high levels of MARCKS transfection/infection copy number and/or interference 
due to the presence of endogenous MARCKS. Unfortunately, practical utility of MRP and 
MARCKS-deficient mice has been severely hindered by the perinatal lethality of the mice due 
to neurological problems (Stumpo, et al., 1995; Swierczynski, et al., 1996). 
MARCKS Family and Disease
Since MARCKS and MRP have been implicated as critical regulators of important cel-
lular processes like regulated exocytosis, cell attachment, and cell mobility, it is not surprising 
that these proteins are being investigated for possible links to disease. The diseases studied in 
relation to the MARCKS family range from neurological pathologies to cancer and inflamma-
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tion disorders. What all of these investigations have in common is that they apply previously 
purported MARCKS functions to their ramifications for pathological conditions. 
The perinatal lethality of MARCKS-deficiency in mice, due to failure of the neural 
tube to close, implicates an important role for MARCKS in normal neurological development. 
Three types of neuropathies are currently linked to MARCKS. First, when a peptide corre-
sponding to the PSD sequence of MARCKS (MPSD) was acutely infused into the hippocam-
pus of rats, it resulted in significant in vivo impairment of working (changing) memory, along 
with a smaller impairment of long-term reference memory, as assessed by performance in a 
16-arm radial arm maze (Timofeeva, et al., 2009). A possible mechanism of action, though, for 
this effect is extracellular inhibition of nicotinic acetylcholine receptors preventing activation 
of neurotransmitter release (Gay, et al., 2008, Timofeeva, et al., 2009). This research suggests 
that MARCKS could be a target for cognitive impairment diseases, such as Alzheimers. Sec-
ond, MARCKS overexpression has been linked to the most malignant type of adult brain tu-
mor, glioblastoma multiforme (GBM). Both operative specimens and xenograft explant tumors 
significantly overexpressed MARCKS protein. In glioma cell lines transfomed to simulate the 
conditions found in 50% of all GBMs, overexpression of epidermal growth factor (EGF) re-
ceptors, MARCKS was subsequently upregulated. To validate these overexpression results, re-
searchers showed that siRNA knockdown of MARCKS in these same glioma cells significant-
ly decreased cell attachment and invasion compared to control (Micallef, et al., 2009). Thus, 
according to these two studies, MARCKS may be involved in neuronal plasticity and could 
function as a promoter of tumor invasiveness. Finally, a recent, though tentative connection has 
been suggested between MARCKS and psychiatric diseases. Alterations in PKC’s activation 
state result from therapeutic treatments for diseases like bipolar disorder, mania, depression 
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and schizophrenia (Szando, et al., 2009; Kim, et al., 2009). In mania, manic episodes are as-
sociated with increased PKC activity marked by increased levels of phosphoMARCKS protein 
in the prefrontal cortex membrane. Lithium, an anti-mania treatment, significantly decreased 
these levels of phosphoMARCKS (Szando, et al., 2009). Another therapy for treating mood 
disorders, electroconvulsive treatment, when modeled in rats resulted in a temporal increase 
in phosphorylation of three major brain PKC substrates, one of which was MARCKS (Kim, et 
al., 2009). Since this finding is recent, the specific connection to any MARCKS function has 
not yet been investigated. Only further studies will reveal whether or not MARCKS could be 
a future therapeutic target for mood disorders. 
A function for MARCKS family members has also been implicated in numerous 
cancer studies for playing a role in cell invasion, an important component of cancer 
metastasis. Invasive bladder cancer cells, treated with phorbol ester to keep MARCKS per-
petually phosphorylated, resulted in reduced cell motility and invasiveness (Yokoyama, et al., 
1998). Another group, in contrast, showed that treatment of cells with microRNA targeting 
MARCKS led to increased invasion of prostate cancer cells, suggesting MARCKS as a possi-
ble tumor suppressor in prostate cancer (Li, et al., 2009). It seems that increased levels of phos-
phorylated MARCKS could act as a metastatic tumor suppressor, while decreased levels of to-
tal MARCKS protein could promote tumor invasiveness. The answer could be as simple as the 
fact that MARCKS function in suppressing tumor invasiveness correlates to its activation via 
phosphorylation: if less MARCKS is available for phosphorylation, less MARCKS-mediated 
inhibition of invasiveness occurs. Unfortunately, a clear mechanistic model of MARCKS func-
tion as a tumor suppressor has not yet been elucidated. 
Knockdown of MRP, the other MARCKS family member, in a transformed murine 
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Fig. 1.3:  MARCKS-Mediated Actin Barrier Hypothesis. At rest, the actin barrier nega-
tively regulates secretion, but after receptor activation actin filament disruption results in SGs 
docking to the PM where exocytosis eventually occurs. The mechanism of actin destabiliza-
tion, while it remains unknown, is believed to involve PKC phosphorylation of MARCKS, 
which induces MARCKS’ translocation from the PM to the cytosol. However, the causal re-
lationship between MARCKS’ translocation and the actin barrier destabilization has not been 
rigorously studied. PhosphoMARCKS has also been suggested to associate with SGs after 
translocation and could be involved in SG trafficking to the PM.
14
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mammary cell line and in a prostate cancer cell line decreased tumor cell migration and inva-
sion, opposite to findings with MARCKS. These results suggested that MRP might act as a 
promoter of tumor invasiveness. Confusingly, though, the same study demonstrated that the 
inhibition of MRP expression correlated to decreased tumor numbers and size in oncogenic 
mice. Conclusions drawn by the researchers were that MRP is involved in adherens junction 
formation, and that it promotes invasiveness in the early stages of metastasis, while inhibiting 
the signaling required for the later stages of tumorigenesis (Finlayson & Freeman, 2009). All 
results, therefore, only indicate that both MARCKS family members are involved in tumor cell 
attachment and invasion, with contradiction between MARCKS and MRP studies suggesting 
they may either be tumor suppressors or promoters. 
In another pathology area, arthritis, MARCKS gene expression was found to be up-
regulated in normal human chondrocytes when they were exposed to the pro-inflammatory 
cytokine-loaded supernatant of rheumatoid arthritis (RA) synovial fibroblasts. The upregula-
tion of MARCKS was also correlated with increased joint structure damage due to increased 
chondrocyte secretion of matrix degrading proteins (Andreas, et al., 2009). However, research-
ers did not indicate whether human chondrocytes from RA patients pathologically express 
higher levels of MARCKS compared to non-RA patients. The evidence linking MARCKS to 
joint structure degradation remains correlative, rather than causative, but the initial correlation 
is well demonstrated. 
MARCKS and Regulated Exocytosis
The role of MARCKS in regulated exocytosis has been investigated for almost a de-
cade. Since MARCKS-deficient mice die perinatally (Stumpo, et al., 1995; Swierczynski, et 
16
al., 1996), alternative experimental approaches have been used; most commonly applying syn-
thetic peptides representing the conserved MARCKS domains to study the resulting effects 
on secretion. In chromaffin cells, a PKC-dependent, MARCKS-dependent role is postulated 
based on the evidence that permeabilized cells treated with the MARCKS PSD (MPSD) pep-
tide, which inhibits MARCKS phosphorylation, have a decreased rate of catecholamine re-
lease (Doreian, et al., 2009). Significantly, a control peptide, in which the PKC-phosphorylated 
serines were mutated to alanines, showed no inhibition of MARCKS phosphorylation. This 
model is supported by the further observation that MARCKS knockdown with siRNA reduced 
cortical F-actin disassembly and catecholamine secretion, measured as a decrease in vesicle 
fusion events (Rose, et al., 2001; Jerdeva, et al., 2005; Park, et al., 2006). Taken together, these 
results suggest that for regulated exocytosis of neurotransmitters, phosphorylated MARCKS 
serves a positive regulatory role in cortical F-actin disassembly and chromaffin cell secretion. 
In platelets, when the MPSD peptide inhibited the regulated exocytosis of serotonin, the same 
critical positive regulatory role was suggested (Elzagallaai, et al., 2000). Thus, in aggregate, 
these studies suggest that MARCKS is an important regulator of regulated exocytosis. 
A major criticism, however, of studies utilizing the MPSD is that the peptide may affect 
secretion by inhibiting extracellular receptor activation (Gay, et al., 2008) or by competing with 
all PKC substrates, not just by its MARCKS-specific effects, . The possibility of non-specific 
effects being attributed to MARCKS-specific functions is an important issue, particularly in 
cells also expressing MRP and other polybasic domain proteins with PSD homology (GAP43, 
CAP23, Adducins, A kinase anchoring protein 12 and 79) (Aderem, 1995; Matsuoka, Li, & 
Bennett, 2000; Streb & Miano, 2005). The answer to how the MPSD functions mechanistically 
would give insight into answering these issues of specificity. 
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PSD peptide studies, though, are not the only investigations linking MARCKS to 
regulated exocytosis. Studies in a human intestinal endocrine cell line (BON) demonstrated 
that MARCKS overexpression increased neurotensin secretion, whereas MARCKS siRNA 
knockdown inhibited secretion. Additionally, the ability of MARCKS overexpression to en-
hance regulated exocytosis was neutralized in full-length MARCKS mutants lacking PKC 
phosphorylation or myristoylation (Li, et al., 2005). In oocyte cortical granules, exocytosis 
has been shown to require phosphorylatable MARCKS, not just actin depolymerization and 
PKC activation (Eliyahu, et al., 2005; Eliyahu, et al., 2006). In aggregate, these studies suggest 
that MARCKS membrane binding, phosphorylation and subsequent translocation is critical for 
MARCKS positive regulatory role in regulated exocytosis.
Another study demonstrated an upregulation of MARCKS expression in human cho-
nodrocytes, while also observing an increase in secretion. In this study, when the cytokine-rich 
supernatant from synovial fibroblasts of rheumatoid arthritis patients was placed in culture 
with human chondrocytes, MARCKS’ gene expression was upregulated. The secretion from 
these human chondrocytes was also potentiated (Andreas, et al., 2009). This study, however, 
does not provide any causal link between the change in MARCKS expression and the increased 
chondrocyte secretion. It is possible that the increased levels of pro-inflammatory cytokines 
could alone enhance secretion, while the presence of an activated immune situation upregu-
lates MARCKS for an unrelated purpose. 
MARCKS Translocation
Much of the evidence for MARCKS’ role in regulated exocytosis is centered on the 
ability of MARCKS to be phosphorylated by PKC and translocate from the PM to the cyto-
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sol. A mechanism proposed by Stuart McLaughlin for this cycling on and off the membrane 
is the myristoyl-electrostatic switch model. Briefly, insertion of the myristoyl moiety of un-
phosphorylated MARCKS into the PM provides a weak interaction that stabilizes the protein 
on the PM. Positively charged residues on the basic PSD electrostatically interact with acidic 
phospholipids while its five Phe residues insert into the hydrophobic region of the lipid bilayer. 
These multiple weak interactions synergistically create a tight membrane association. Phos-
phorylation by PKC of three serine residues within the PSD neutralizes its positive charges, 
destabilizing association between MARCKS and the PM, inducing translocation to the cytosol 
(Tzlil, et al., 2008; Seykora, et al., 1996). However, the functional significance of this translo-
cation is not yet understood in detail, but an early suggestion was that the PSD bound the cor-
tical actin filaments of the actin barrier in secretory cells. In this model, MARCKS in resting 
cells anchors actin filaments to the PM, stabilizing the actin barrier, and MARCKS transloca-
tion destabilizes the actin filaments, resulting in actin barrier disruption (Trifaro, et al., 2002; 
Jerdeva, et al., 2005; Park, et al., 2006). 
The importance of MARCKS’ translocation for normal cell spreading on the extracel-
lular matrix proteins, particularly fibronectin, a ligand for the α5β1 integrin-mediated receptor 
signaling pathway has also been demonstrated (Disatnik, et al., 2004; Myat, et al., 1997). Two 
independent studies demonstrated parallel results in fibroblasts and myoblasts, respectively, by 
utilizing overexpression of MARCKS mutants. In fibroblasts, overexpression of a MARCKS 
mutant, in which the reversible membrane binding of a single myristoyl group was mutated to 
the more permanent binding of two palmitoyl groups, prevented translocation to the cytosol 
following PKC phosphorylation. Inhibition of MARCKS translocation resulted in attenua-
tion of cell spreading into lamellae and impaired cell spreading on the fibronectin substratum 
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Fig. 1.4:  Two possible mechanisms for MARCKS-mediated actin barrier disruption
(A) The Actin Tethering Model proposes that actin filaments are tethered to the PM by bind-
ing to two unphosphorylated MARCKS. When MARCKS is phosphorylated and translocates, 
these actin filaments are destabilized. 
(B) The PIP2 Sequestration model proposes that MARCKS sequesters PIP2, an important 
signaling molecule, and upon translocation releases PIP2 for its various functions, including 
actin destabilization.
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(Myat, et al., 1997). In myoblasts, full-length MARCKS mutants insensitive to PKC phos-
phorylation also inhibited cell spreading and corresponded to decreased actin polymerization 
and focal adhesion formation. Significantly, these researchers elucidated another critical com-
ponent of the MARCKS translocation process. When phosphatase inhibitors were added, the 
prolonged presence of full-length phosphoMARCKS, localized to the cytosol, also inhibited 
cell spreading (Disatnik, et al., 2004). Consequently, the role of MARCKS in cell spreading 
seems to require the ability of MARCKS to bidirectionally translocate from the PM to the cy-
tosol and back. In fact, a study of a transformed astrocytoma cell line in which MARCKS was 
knocked down with two different siRNAs, demonstrated impaired cell attachment, spreading, 
and motility (Micallef, et al., 2009). Most notably, the cells had a “rounded morphology” just 
as Disatnik, et al., 2004, described. The conclusion is that lack of reversible translocation, due 
to decreased amounts of MARCKS or due to inability to detach from the PM, all result in a 
similar rounded cell morphology, impaired cell spreading, and possibly impaired motility.
Proposed Mechanisms for MARCKS-mediated Regulated Exocytosis
This process of reversible, bidirectional movement of MARCKS between the PM and 
the cytosol has become the model subcellular behavior included in any proposed mechanism 
for MARCKS function (Fig. 1.3). Interestingly, timing of actin barrier disruption correlates 
with PKC phosphorylation of MARCKS and its translocation to the cytosol (Arbuzova, et al., 
2002; Ehre, et al., 2005). Down-regulation of MARCKS using a MARCKS N-terminal se-
quence (MANS) peptide has been shown to diminish mucin secretion, but the peptide’s speci-
ficity to MARCKS and its unknown mechanism of action raise important questions (Singer, et 
al., 2004; Li, et al., 2001). Consequently, MARCKS’translocation remains indirectly linked to 
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destabilization of the actin barrier and exocytic secretion. 
Existing evidence supports the relationship between MARCKS activation and secre-
tion; however, the three major models for the mechanistic function of MARCKS propose three 
distinct mechanisms of action. 
1. MARCKS operates as a tether between actin filaments of the barrier and the PM 
when secretory cells are at rest. This model (Fig. 1.4 A) is derived from studies demonstrat-
ing that a peptide corresponding to the non-phosphorylated MARCKS PSD is capable of in 
vitro binding and cross-linking of filamentous actin (F-actin). This activity corresponds well 
with the hypothesis that unphosphorylated MARCKS effectively binds F-actin, tethering the 
cortical actin barrier to the PM. Correlatively, phosphorylated PSD peptides were observed 
to have reduced binding affinity for F-actin, along with decreased cross-linking activity, sug-
gesting that phosphorylation of MARCKS PSD by PKC induces a conformational change that 
diminishes accessibility to the actin binding sites (Yarmola, et al., 2001; Tapp, et al., 2005). 
Consequently, this mechanism proposes that prior to PKC phosphorylation, MARCKS tethers 
actin filaments to the PM, but after PKC phosphorylation, MARCKS translocation destabilizes 
the barrier (Trifaro, et al., 2002; Jerdeva, et al., 2005; Park, et al., 2006). 
It is known, however, that full-length MARCKS does not exhibit as marked an ability 
to bind or cross-link actin as the PSD peptide alone, and studies directly testing MARCKS’ 
interactions with actin in living cells have not been performed to date (Yarmola, et al., 2001; 
Tapp, et al., 2005). According to this model, MARCKS-deficiency results in loss of actin 
tethering and disruption of the actin barrier, even under resting conditions. Hence, we should 
observe increased regulated secretion, possibly even under baseline conditions in MARCKS-
deficient cells. 
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2. MARCKS sequesters phosphatidylinositol 4,5-bisphosphate (PIP2) in the PM. 
Stoichiometrically, one MARCKS PSD can electrostatically sequester three to four PIP2 mol-
ecules (Fig. 1.4 B). In aggregate, the MARCKS PSD is believed to be capable of sequestering 
a significant fraction of PIP2 in membranes in vitro (Wang, et al., 2001; Wang, et al., 2002; 
Tzlil, et al., 2008). PIP2 is the substrate for the second messengers DAG and IP3, as well as an 
activator of many cytoskeletal regulatory proteins involved in polymerization and treadmilling 
(Sundaram, et al., 2004). These cytoskeletal regulators may include phospholipase D (PLD), an 
activator which induces downstream release of phosphatidic acid, and WASP proteins, which 
promote formation of Arp 2/3 complexes (Caroni, 2001; Sundaram, et al., 2004). Free PIP2 
in the PM can inhibit actin-severing molecules like scinderin, promoting actin nucleation and 
polymerization at the PM (Trifaro, et al., 2000). Sequestration of PIP2 in MARCKS-enriched 
microdomains would reduce these PIP2 activities within the PM. Upon receptor activation 
and MARCKS translocation, local PIP2 pools become available for lateral diffusion in the PM 
where it will be available to PLC for conversion into DAG and IP3 (Wang, et al., 2001); ad-
ditionally, it will activate PLD and cytoskeletal remodeling proteins necessary for SG delivery 
and fusion to the PM (Wang, et al., 2001; Trifaro, et al., 2002; Wang, et al., 2002). With this 
model, unphosphorylated MARCKS sequesters PIP2, creating a local PIP2 reservoir which 
MARCKS translocation would release, allowing generation of DAG and IP3. These second 
messengers would in turn activate calcium signaling to release scinderin to sever the actin 
barrier filaments and initiate the necessary SG trafficking. Accordingly, MARCKS-deficient 
cells would have increased PIP2-mediated stabilization of the cortical actin barrier, resulting 
in decreased regulated secretion, contrary to the increased secretion predicted by Figure 1.4A.
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3. MARCKS tethers actin filaments to secretory granule membranes for transit to the 
PM. Recent advances have demonstrated that actin filaments do not simply play an inhibitory 
role in regulated exocytosis via the actin barrier, but that de novo actin polymerization around 
the SGs may also be important for SG delivery to the PM (Caroni, 2001; Eitzen, 2003; Park, et 
al., 2006). As described in model #1, MARCKS can bind to and cross-link F-actin (Yarmola, 
et al., 2001; Tapp, et al., 2005). Recent data also suggest that MARCKS associates with SG 
membranes, tethering actin filaments to the SG membrane for trafficking to the PM (Singer, et 
al., 2004). Evidence of MARCKS associating with lysosomal membranes has been previously 
demonstrated, and intracellular membrane association implicated based on FRAP (fluorescent 
recovery after photobleaching) experiments showing that MARCKS is relatively immobile 
once it translocates to the cytoplasm (Ohmori, et al., 2000 ; Allen & Aderem, 1995). However, 
it is not clear whether MARCKS must associate with SG membranes to carry out its function 
in regulated exocytosis (Singer, et al., 2004). According to this model, MARCKS-deficiency 
would be expected to reduce exocytic release by impairing SG trafficking. This mechanism 
proposes a regulatory role for MARCKS independent of the negative or positive regulatory 
roles in actin barrier disruption, as predicted by the two previous hypotheses. 
MARCKS’ role in regulated exocytosis remains incompletely understood. If unphos-
phorylated MARCKS is involved as a tether, which connects the actin barrier to the PM, 
increased mobility permitted by absence of MARCKS would result in increased regulated 
exocytosis, per the actin-tethering model. However, the same increased regulated exocytosis 
would not be expected if MARCKS is instead involved in PIP2 sequestration. If MARCKS is 
involved in other stages of cytoskeletal remodeling, a decrease in regulated exocytosis would 
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be expected due to interference with actin dynamics necessary for SG delivery to the PM. If 
MARCKS is involved in both actin barrier disruption and SG trafficking, the observed effects 
on regulated exocytosis would be much more convoluted. As a first step in unraveling the 
complexities of MARCKS function in regulated secretion, we tested whether or not MARCKS 
is essential for the process, using embryonic mast cells from MARCKS-deficient mice (Kita-
mura, et al., 1979; Xia, et al., 1997).
Physiological Significance of Mast Cells 
Mast cells are key players in inflammatory reactions of all kinds, including acute and chron-
ic allergic reactions, as well as innate immune responses to pathogens (Watanabe, et al., 1999; 
Bischoff & Kramer, 2007; Metz & Maurer, 2007, Metcalfe, 2008). These cells can be found 
in two states: immature, bone marrow-derived progenitors and mature, mast cells adherent to 
tissue (Jamur, et al., 2005; Metcalfe, 2008). Various receptor pathways can activate mast cells 
resulting in initiation of the inflammatory response, infiltration and differentiation of numerous 
immune cells and resulting pathological complications. In humans, a disease termed masto-
cytosis, characterized by the aberrant proliferation of mast cells, has expanded into a group 
of seven pathological variants, ranging in severity and prognostic life expectancy (Metcalfe, 
2008). In cardiac tissue, resident mast cells have been implicated in ischemia reperfusion in-
jury, graft rejection after cardiac transplant and beginning and end-stage cardiac hypertrophy 
leading to cardiac failure (Shiota, et al., 2003; Balakumar et al., 2007). 
In the respiratory system, mast cell activation can lead to a hypersensitivity response 
resulting in excessive mucus secretion in the upper airways and lungs, as well as lung edema 
and bronchospasms associated with asthma (Prussin & Metcalfe, 2003; Metz & Maurer, 2007 
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Fig. 1.5:  Mast cell regulated exocytic pathways
 Mast cell regulated exocytosis can be activated through various receptors. FceRI, is a tyrosine 
kinase receptor commonly utilized in mast cell secretion studies. G-protein coupled recep-
tors present in the membrane vary by tissue, but often include complement receptors and 
proteinase-activated receptors (PARs). Activation of PLC by either receptor pathway results 
in generation of the second messengers DAG and IP3. DAG activates PKC, which would in 
turn phosphorylate MARCKS and induce MARCKS translocation to the cytosol. Both IP3 
and Sphingosine-1 phosphate (S1P) are signaling molecules that can be activated to mobilize 
calcium for secretion. 
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Gonzalo, et al., 2007). Polymorphonuclear cell (PMN) infiltration is part of a typical inflam-
matory response and in pathological situations can result in significant tissue damage. Under 
conditions of allergic sensitization, lung alveoli of mast cell-deficient mice were found to have 
significantly attenuated PMN infiltration compared to mast cell-sufficient controls. This mast 
cell-deficiency did not affect initial alveolar inflammation, probably initiated by resident mac-
rophages, rather only affecting the resulting PMN chemotaxis (Baumann et al., 2001). Another 
study showed that increased mast cell accumulation sensitized mice so that an enhanced in-
flammatory response was observed for both antigen-mediated and chemically-induced activa-
tion (Kalin, et al., 2008). Additionally, multiple regulated exocytic products of mast cells have 
been linked to the airway hypertensive response associated with asthma and bronchoconstric-
tion (Bradding, et al., 2006; Gonzalo, et al., 2007; Ryzhov, et al., 2008). Exocytic release of 
the CC chemokine ligand 1 (CCL1) has been identified as a mast cell-dependent product that 
triggers the pulmonary inflammation response, including mucus hypersecretion. The study in-
cluded the observation that asthmatics had a five-fold increase in the level of CCL1, indicating 
that mast cell regulated exocytosis significantly contributes to the airway hyperresponsiveness 
and inflammation associated with asthma (Gonzalo, et al., 2007). 
In the systemic circulation, mast cells contribute to multiple kinds of hypersensitivity 
including acute inflammatory responses and autoimmune vasculitis (necrotizing inflammation 
of vessel walls). Mast cell-deficient mice showed significantly attenuated PMN infiltration 
when cutaneous vasculitis was induced in vivo. These observations are donor variable and 
have been attributed to FcγRs and complement receptors found on mast cells (Baumann et al., 
2001; Watanabe et al., 1999). Additionally, the ability to induce skin vasculitis in FcR-deficient 
mice was returned with transfer of wild type bone marrow-derived mast cells, but not macro-
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phages (Sanchez-Mejorada and Rosales, 1998; Baumann et al., 2001; Watanabe et al., 1999). 
All of these roles for mast cells result from their ability to release numerous pro-inflammatory 
mediators, such as TNF-α, interleukins, lipid mediators, tryptase, chymase, serotonin and his-
tamine into the resident tissue through regulated exocytosis upon receptor activation (Metz and 
Maurer, 2007; Prussin and Metcalfe, 2003). 
Mechanism of Mast Cell Degranulation 
The mechanism by which mast cell degranulation induces these multiple immune func-
tions has long been studied. Mast cell degranulation (Fig. 1.5) is a form of regulated exocytosis 
and can be mediated through the receptor tyrosine kinase FcεRI, a high affinity immunoglobu-
lin E (IgE) receptor (Stinchcombe et al., 2004). FcεRI belongs to a family of membrane recep-
tors found on hematopoietic cell types recognizing different immunoglobulins. Specifically, 
IgE-mediated degranulation has been linked to cutaneous and systemic anaphylaxis (Sanchez-
Mejorada and Rosales, 1998; Watanabe et al., 1999; Baumann et al., 2001). 
In the process of degranulation, IgE is involved in a positive feedback loop. Presence 
of IgE increases the surface expression of FcεRI, which in turn enhances mediator release 
upon antigen activation (Yamaguchi, et al., 1999). This corresponds well with the idea of 
type I hypersensitivity after passive sensitization. First, IgE binds to the FcεRI. Antigen bind-
ing to this immune complex crosslinks and activates the receptor, inducing tyrosine kinase 
phosphorylation. Tyrosine phosphorylation activates Spleen tyrosine kinase (Syk), which ini-
tiates numerous pathways for mediator formation, degranulation and calcium mobilization. 
Calcium mobilization is an obligate event for degranulation and is mediated through the sec-
ondary messenger sphingosine-1-phosphate (S1P) and inositol trisphosphate (IP3) for tyrosine 
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kinase receptors (Lee et al., 2005). Notably, Syk activates PLC inducing the formation of 
diacylglycerol (DAG), which activates PKC to act on its substrates (Sanchez-Mejora-
da and Rosales, 1998). Other membrane receptors of the FcR family, the FcγRs, bind 
immunoglobulin G (IgG) and operate via much the same mechanism. These have been shown 
through gene disruption studies to be the key players in type III systemic anaphylactic re-
sponses and PMN infiltration-derived tissue damage. 
The other class of receptors involved in mast cell degranulation is G protein-coupled 
receptors (GPCRs). Numerous GPCRs can be found on mast cells including protease-activat-
ed receptors (PARs), peptide receptors, and purinergic receptors (Suto, et al., 1996; van der 
Kleij et al., 2003; Bulanova, et al., 2005). The pathway each receptor initiates is diverse and 
dependent on different G proteins. Since MARCKS is regulated by PKC phosphorylation and 
present in WT eHMCs (Fig. 2.1), regulated exocytic pathways involving PKC activation can 
be used to determine the specific effects of MARCKS on secretion utilizing null MARCKS 
embryonic hepatic-derived mast cells (eHMCs) (Kitamura, et al., 1979; Xia, et al., 1997).
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Chapter 2
MARCKS acts as a negative modulator of FcepsilonR-mediated mast cell  
regulated exocytosis
ABSTRACT
A variety of data on Myristoylated alanine-rich C kinase substrate (MARCKS) suggest 
a possible correlation between its plasma membrane (PM) to cytosol translocation in activated 
secretory cells and regulated exocytosis. Unfortunately, the MARCKS null mouse, with its 
perinatally lethal phenotype caused by defects in the development of the neural tube, has 
thwarted efforts to use this mouse model as a tool in determining if the relationship is causal. 
Embryonic mast cells, though, are one type of secretory cell which can be isolated and cultured 
from the MARCKS null mouse. We studied the role of MARCKS in mast cell regulated exo-
cytosis by comparing the secretion of embryonic hepatic-derived MARCKS-sufficient (WT) 
and MARCKS-deficient mast cells stimulated through the high affinity IgE receptor, FceRI. 
When mast cells were stimulated with antigen while in suspension, conditions frequently used 
for mast cell secretion assays, no difference was detected. However, MARCKS-deficient cells 
did demonstrate potentiated secretion compared to WT cells when adherent cells were stimu-
lated, a condition mimicking the microenvironment of mature mast cells in all major organs. 
Kinetically, MARCKS null cells exhibited enhanced early release of secretory cargo versus 
WT-derived cells, suggesting a role for MARCKS as a negative regulator of secretion. As an 
independent approach, we applied peptides with N-terminal sequences that are purported to 
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exercise a MARCKS-specific inhibition to the mast cells and found no MARCKS-specific 
inhibition: both WT and MARCKS-deficient cells were inhibited equally. Thus, MARCKS ap-
pears not to be essential in regulated exocytosis in mast cells. It appears, instead, to modulate 
secretion in a negative fashion, by mechanisms that remain to be elucidated.
34
INTRODUCTION
MARCKS and the homologous MRP comprise a two-member gene family. Both were 
discovered as PKC substrates regulated developmentally and spatially (Blackshear, 1993; Yo-
koyama, et al., 1998) and purportedly serve many diverse functions in cell adhesion, motility 
and secretion. Typically, both are intimated to effect these functions through regulation of the 
actin cytoskeleton (Umekage & Kato, 1991; Blackshear, et al., 1992; Lobach, et al., 1993; Yo-
koyama, et al., 1998; Chu, et al., 2002; Arbuzova, et al., 2002; Disatnik, et al., 2004; Eckert, 
et al., 2010). MARCKS, specifically, has been implicated as a regulator of regulated exocy-
tosis in a wide variety of immune, endocrine, and exocrine secretory cell types (Rose, et al., 
2001; Li, et al., 2001; Singer, et al., 2004; Li, et al., 2005; Eliyahu, et al., 2005; Eliyahu, et al., 
2006; Park, et al., 2006). Cargo for regulated exocytosis is stored in secretory granules (SGs) 
or vesicles, which, following cell activation and initiation of second messenger signaling, ne-
gotiate through a network of cortical actin filaments lying between them and the PM. Rapid 
disruption and remodeling of the actin allows SGs to migrate to exocytic docking sites on the 
PM, enabling SNARE-mediated fusion and cargo exocytosis (Bader, et al., 2004; Malacombe, 
et al., 2006; Rizo, et al., 2006). 
Notably, the regulatory components involved in the remodeling of cortical actin remain 
significantly less well understood than other portions of the regulated exocytic pathway (Bad-
er, et al., 2004; Malacombe, et al., 2006). Some studies have linked MARCKS to regulated 
exocytosis without implicating any particular mechanism of action (Elzagallaai, et al., 2000; 
Li, et al., 2005; Doreian, et al., 2009), while others have specifically investigated the relation-
ship between MARCKS and actin dynamics (Rose, et al., 2001; Jerdeva, et al., 2005; Park, et 
al., 2006). A hypothesis for the initial disruption of cortical actin postulates that the proteins 
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MARCKS and scinderin regulate this event (Vitale, et al., 1991; Rose, et al., 2001; Trifaro, et 
al., 2002; Arbuzova, et al., 2002; Pene, et al., 2005). In resting cells, MARCKS is found local-
ized to the PM along with the cortical actin filaments (Ehre, et al., 2005; Malacombe, et al., 
2006). Previous experiments have demonstrated that following extracellular activation, mul-
tiple PKC isoforms are activated and MARCKS, a major PKC substrate, is among the proteins 
phosphorylated (Lobach, et al., 1993; Aderem, 1995; Trifaro, et al., 2002). PKC phosphory-
lation induces MARCKS to translocate from the PM to the cytosol, which according to the 
hypothesis, results in actin destabilization by removal of its tether to the PM. Ca2+-activated 
scinderin-mediated filament severing may also contribute to this process (Ohmori, et al., 2000; 
Trifaro, et al., 2000; Trifaro, et al., 2002). With actin filament destabilization, the SGs access 
exocytic docking sites, fuse with the PM, and release their cargo (Bader, et al., 2004; Mala-
combe, et al., 2006; Rizo, et al., 2006; Davis & Dickey, 2008). 
Chromaffin cell secretion studies have led to the proposal of a significant role for 
MARCKS in regulated exocytosis, based on experiments where treatment of cells with 
MARCKS PSD peptides and siRNA decreased regulated secretion (Rose, et al., 2001; Park, 
et al., 2006; Doreian, et al., 2009). Taken together, these results suggest that MARCKS is 
a positive, possibly essential, regulator of regulated exocytosis. Similar results were shown 
for regulated exocytosis in platelets (Elzagallaai, et al., 2000;), oocytes (Eliyahu, et al.,2005; 
Eliyahu, et al., 2006), normal human bronchial epithelial cells (Li, et al., 2001; Singer, et al., 
2004), and endocrine cells (Liu, et al., 1994; Rose, et al., 2001; Li, et al., 2005; Jerdeva, et 
al., 2005; Park, et al., 2006; Doreian, et al., 2009). We sought to test whether the complete 
absence of MARCKS affected regulated exocytosis in a similar manner, by making use of the 
MARCKS-deficient mouse. Since this mouse has a perinatally lethal phenotype due to defects 
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in neural tube closure (Umekage & Kato, 1991; Blackshear, et al., 1992; Lobach, et al., 1993), 
we adapted culture systems for growing embryonic hepatic-derived mast cells to address this 
question (Xia, et al., 1997). 
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MATERIALS & METHODS
Mast Cell Culture and Isolation
Bone marrow-derived mast cells (BMMCs) were isolated from the femurs of 6–10 
week old C57/BL6J. Once isolated, cells were cultured in complete medium consisting of 
RPMI 1640 media supplemented with L-glutamine, 10% fetal bovine serum (FBS), 1M 
Hepes Buffer, non-essential amino acids, sodium pyruvate, b-mercaptoethanol, penicillin/
streptomycin, 20 ng/mL IL-3 (Peprotech), and 20 ng/mL murine stem cell factor (Peprotech) 
and incubated at 37۫ºC in a 5% CO2 atmosphere. Cultures were resuspended into fresh media 
every 3–4 days ,and after 4–5 weeks mast cells were assayed for the presence of the FceRI on 
the cell surface, a marker of mature mast cells (Jamur, et al., 2005).
Embryonic hepatic-derived mast cells (eHMCs) resulting from the mating of either 
MARCKS or MRP heterozygotes were isolated from homogenized livers of E14-E18 em-
bryos on a C57Bl/6J genetic background (Barker, 1968; Xia, et al., 1997). Cells were cultured 
in suspension with complete medium and incubated at 37۫ºC in a 5% CO2 atmosphere for 4–5 
weeks. Mast cells in suspension were resuspended into fresh media every 3-4 days. The ma-
turity of the mast cell cultures was assessed for 5 week old mast cells using the same methods 
described in the following section.
Immunohistochemical Analyses of Mast Cell Purity and Maturation
Five week old mast cells were allowed to adhere overnight to fibronectin-coated glass 
coverslips contained in 6-well plates. Media was then removed from the cells and the cells 
were gently rinsed three times with Siraganian Buffer (SG buffer). Prior to labeling, cells 
were blocked for one hour at room temperature with the mouse CD32/CD16 antibody (1:50) 
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to reduce non-specific labeling of lower affinity IgE FcR family members. Cells were then 
incubated for one hour with the primary mouse anti-DNP IgE antibody (1:25) (BD Biosci-
ences). After three rinses with SG buffer, cells were incubated with a rat anti-mouse FITC-anti 
IgE antibody (BD Biosciences) for one hour at room temperature, then fixed with 4% parafor-
maldehyde (PFA) in PBS for 7 minutes.The coverslips were mounted onto glass slides using 
the Prolong Gold Antifade (Invitrogen) mounting media. Slides were stored in the dark at 
4ºC until the imaging experiments. Approximately 100 cells were analyzed using a widefield 
Leica DMIRB inverted microscope with a 40X oil PlanFluor objective (1.25 NA) and FITC 
dichroic filter settings (Excitation: 480/40; Emission: 535/50). Three independent experiments 
confirmed a >99% pure and mature mast cell population (Suppl. Fig. S1). All microscopy work 
was performed in the Michael Hooker Microscopy Facility at UNC-Chapel Hill. As a second 
staining technique, cells from the same cultures were adhered to coverslips, blocked with the 
CD32/CD16 antibody, as above, and incubated with the mouse FITC-anti FceRI alpha subunit 
antibody (1:25) for one hour at room temperature (eBioscience) before fixation. Coverslips 
were mounted onto glass slides and once more >99% pure culture of mature mast cells were 
detected.
In vitro β-hexosaminidase secretion assays
Cells (1 X 106/ mL) were sensitized overnight at 37۫ºC with DNP-IgE (250 ng/mL; 
clone SPE-7; Sigma). After sensitization, cells were removed from the presence of IgE. For 
suspension assays, cells were centrifuged down and resuspended in fresh media for 24 hours 
prior to activation. For adherent assays, cells were centrifuged down, resuspended in fresh 
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media, and incubated in fibronectin-coated wells (20 ug/mL) of a 96-well plate overnight. 
Complete medium was then replaced with 100 uL of SG Buffer [119 mM NaCl, 5 mM KCl, 
25 mM PIPES disodium salt, 5.6 mM glucose, 1 mM CaCl2, 0.4 mM MgCl2, and 0.1% BSA]. 
Cells were challenged with varying doses of bovine DNP-albumin conjugate (DNP) (1-100 ng/
mL; Calbiochem) or Buffer as control at 37ºC for the time period specified. All dose response 
studies utilized a thirty minute incubation. The amount of secretion was measured as the % of 
total cellular β-hexosaminidase secreted into the supernatant, calculated as (hexosaminidase 
released) / (total hexosaminidase in the supernatant and lysate). Each measurement was taken 
in triplicate and the mean value was calculated from seven or more independent experiments. 
MANS Peptides Studies 
The MANS (MA-GAQFSKTAAKGEAAAERPGEAAVA) and RNS (MA-GTAPAAE-
GAGAEVKRASAEAKQAF) peptides were kindly provided by Dr. Kenneth Adler at North 
Carolina State University. The non-myristoylated MANS (NONG) peptide was synthesized by 
Tufts University Core Facility with the sequence of the MANS peptide but lacking the Glycine 
residue to which the myristoyl moiety is normally attached. Adherent eHMCs were incubated 
overnight with DNP-IgE (250 ng/mL; clone SPE-7; Sigma) at 37ºC, prior to an overnight in-
cubation with fibronectin-coated wells of a 96-well plate. Fifteen minutes prior to activation 
with 3 ng/mL of DNP-BSA, cells were pretreated with SG Buffer containing either 50 or 100 
uM concentrations of one of the MANS peptides: MANS, RNS, or NONG. Cells were then 
activated with 3 ng/mL of DNP-BSA and incubated at 37ºC for thirty minutes. The remaining 
steps of the secretion assay were performed as described in the above in vitro b-hexosamini-
dase secretion assays section.
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3-D Cell Reconstruction
Adherent eHMCs were sensitized overnight at 37ºC with DNP-IgE (250 ng/mL; clone 
SPE-7; Sigma), then incubated for specified time periods on fibronectin-coated (20 ug/mL) 
temperature-controlled glass bottom dishes (Bioptechs). Cells were incubated in a SG buffer 
bath containing the lipophilic membrane dye, FM 4-64 FX fixable analog (Invitrogen). Ten 
minutes after addition of FM 4-64, cells were imaged using Leica SP2 laser scanning confocal 
microscope with a 561 HeNe laser line and a 63X 1.4 NA PlanApo oil objective. Images were 
captured using detector window settings for Texas Red (Excitation: 561 HeNe laser line, Emis-
sion: 580-680). The image series of x-y plane sections were captured at designated steps along 
the z-axis and imported into Volocity (v4.4 Perkin Elmer), a 3-D rendering program. From the 
renderings, cell height and cross-sectional area measurements were quantitated. All micros-
copy work was performed in the Michael Hooker Microscopy Facility at UNC-Chapel Hill.
Cortical Actin Volume Quantitation
Adherent eHMCs were sensitized overnight at 37۫C with DNP-IgE (250 ng/mL; clone 
SPE-7; Sigma), then incubated on fibronectin-coated (20 ug/mL) glass coverslips for 24 hours.
Unadherent cells were aspirated off and cells were fixed with 4% paraformaldehyde. For 15 
minutes, cells were permeabilized with 0.1% Triton X-100 (Sigma), washed, then incubated 
with Alexa Fluor 488-phalloidin for 25 minutes. Coverslips were mounted onto slides and 
imaged using a Leica SP2 laser scanning confocal microscope with a 561 HeNe laser line and 
a 63X 1.4 NA PlanApo oil objective. The z-stack images were then imported into Volocity. 
Each individual cell was isolated as a region of interest and phalloidin intensity, thresholded 
to exclude background intensity, was used to delineate the parameters of the cell. A conflu-
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ent mask was then generated by having any regions of low fluorescent intensity, which were 
encompassed on all sides by areas of high intensity included in the calculation. From the cell 
perimeter determing using the mask applied to each optical section of a cell, cell volume was 
calculated.
Statistical Analysis of Mean Values
Statistical differences between the means of two groups were determined by the un-
paired two-tail student’s t-test. P values below 0.05 are regarded as statistically significant and 
are indicated by asterisks. 
Factorial Combination Analysis
The number of possible combinations for the total sixteen data sets taken six at a time 
were calculated using the equation nCr = n!/(r!(n-r)!) and totaled 8,008. Each possible combi-
nation and its corresponding p-value was generated by MatLab (The MathWorks, Inc., MA) 
software using an algorithm kindly written by Abijhit Gurjarpadhye (Virginia Tech, VA). The 
percent of p-values greater than 0.05 was calculated after sorting the values in ascending order 
using Microsoft Excel.
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Figure 2.1:  WT eHMCs express both homologous MARCKS gene family members 
MARCKS and MRP cDNA levels are shown for both WT (+/+) and MARCKS-deficient
(–/ –) eHMCs. The approximately 400 and 300 kb cDNA products were reverse transcribed 
from equal levels of isolated mRNA.
(A) MARCKS null eHMCs clearly lack MARCKS cDNA, while WT eHMCs demonstrate a 
strong level of expression.
(B) Both MARCKS WT and null eHMCs, express MRP. Significantly, MARCKS-deficient 
cells do not show a compensatory upregulation due to loss of MARCKS. 
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RESULTS
To study the direct effects of MARCKS-deficiency on regulated exocytosis, we first 
adapted a sytstem for isolating, differentiating, and studying secretory cells from mouse em-
bryos, a critical step since gene disruption results in mouse perinatal lethality (Blackshear, et 
al., 1992; Lobach, et al., 1993). We chose to isolate mast cells, immune cells specialized for 
regulated exocytic secretion (Watanabe, et al., 1999; Prussin & Metcalfe, 2003; Shiota, et al., 
2003; Balakumar, et al., 2007; Bischoff & Kramer, 2007; Metz & Maurer, 2007; Metcalfe, 
2008). Previous studies have demonstrated that both MARCKS and MRP are expressed in oth-
er types of immune cells, and even upregulated in response to inflammatory stimuli (Thelen, et 
al., 1990; Rose, et al., 1996; Chang, et al., 1999). 
The most common source for isolating mast cells for in vitro differentiation is from 
the bone marrow of 6-12 week old mice, where immature, mast cell progenitors are located 
(Jamur, et al., 1995). Since this isolation source was a system unsuitable for our purposes, we 
adapted the technique to isolate mast cells from embryonic livers, a tissue source where ma-
ture mast cells would be localized (Barker, 1968; Xia, et al., 1997), allowing us to obtain WT, 
MARCKS-deficient, and MRP-deficient embryonic hepatic-derived mast cells (eHMCs). The 
use of eHMCs as a mast cell secretory system was validated by comparing the responsivity of 
WT BMMCs, derived from adult mice, to eHMC cultures activated with ionomycin, (Suppl. 
Fig. S2), phorbol ester-mediated enhancement of ionomycin response (Suppl. Fig. S3), and 
antigen stimulation of the high-affinity IgE tyrosine kinase receptor, FceRI (Suppl. Fig. S5). 
Phorbol ester-mediated enhancement of ionomycin activation in mast cells did exhibit one 
variation between WT BMMCs and eHMCs. While pretreatment with almost all PMA doses 
increased BMMC responsivity to activation with 0.5 uM ionomycin, eHMCs demonstrated 
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no significant difference at any PMA dose when activated with 0.5 uM ionomycin (results not 
shown). However, when eHMCs were pretreated with PMA at varying doses and stimulated 
with a lower dose of ionomycin, 0.25 uM, a similar enhancement of secretion was observed in 
eHMCs. Thus, overall, results from both systems were comparable, and secretory responses 
were within the range of previously published data in every case (Sudo, et al., 1996; Hua, et 
al., 2007; Ryzhov, et al., 2008; Melicoff, et al., 2009).
The lack of MARCKS cDNA expression was confirmed in MARCKS-deficient 
eHMCs; WT and MARCKS null cells expressed similar levels of MRP cDNA (Fig. 2.1). To 
determine the effects of MARCKS-deficiency on the ability of mast cells to exocytose SG con-
tents, we measured the activity of secreted b-hexosaminidase, an enzyme contained within the 
SGs. WT and MARCKS-deficient eHMCs under suspension conditions were compared and, 
surprisingly, no differences in secretory behavior were detected. Both genotypes demonstrated 
similar responsivity for both spontaneous release (4.25+/- 0.71 versus 2.89+/- 0.68% of total 
hexosaminidase content) and FceRI-stimulated regulated exocytosis (maximal stimulated re-
lease of 17.25 +/- 2.48 versus 20.92 +/- 3.46% of total hexosaminidase content) (Suppl. Fig. 
S6). 
Mature mast cells, unlike the hematopoietic mast cells in the bone marrow, are found 
localized in, and adherent to, the extracellular matrix of resident and target organ tissue (Kita-
mura, 1979; Columbo, et al., 1995; Metcalfe, 2008). When mast cells were adhered to substra-
tum proteins of the extracellular matrix, an increase in mast cell sensitivity to agonist stimula-
tion was demonstrated, an effect attributed to a primed state of cell activation for adherent cells 
(Vuori & Ruosahlti, 1993; Columbo, et al., 1995; Kruger-Krasagakes, et al., 1999). Notably, 
MARCKS expression has also been shown to be increased in immune cells primed for immune 
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Figure 2.2:  Adherence to fibronectin enhances regulated exocytosis in WT eHMCs
WT eHMCs were primed with anti-DNP IgE and either allowed to adhere to fibronectin (open) 
(n=16) or left in suspension (filled) (n=7) for 24 hours prior to stimulation with DNP-BSA for 
thirty minutes. 
Values were measured as the amount of b-hexosaminidase activity released into the superna-
tant compared to the total activity from both supernatant and cell lysate. The release of cells 
stimulated through FceRI was subtracted from the spontaneous release from unactivated cells. 
(Error bars represent S.E.; ** p<0.01.; ***p<0.001) 
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Figure 2.3:  MARCKS-deficiency enhances regulated exocytosis in adherent cells 
(A) WT (+/+) and MARCKS-deficient (– / –) eHMCs were adhered to fibronectin for 24 hours 
prior to stimulation with DNP-BSA at five different doses for thirty minutes. The amount of 
hexosaminidase release from the cells, after subtraction of spontaneous release (<5%), is com-
pared between WT (n=16) and MARCKS-deficient (n=16) cells in a dose-effect study. 
(B) The amount of total hexosaminidase activity, a measure of the amount of hexosaminidase 
content released and contained within the cell, was similar between WT (n=16) and MARCKS 
null cells (n=16). 
(Error bars represent S.E.; * p<0.05; *** p<0.001)
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challenge (Thelen, et al., 1990; Rose, et al., 1996; Chang, et al., 1999). Therefore, we tested 
the secretory responses of adherent WT and MARCKS-deficient eHMCs after adherence to 
fibronectin for 24 hours. WT eHMC secretion levels from cells adhered to fibronectin, prior to 
DNP stimulation, experimentally confirmed the observations from previous studies by dem-
onstrating an approximately three-fold increase in the amount of secretion compared to cells 
stimulated under suspension conditions (Fig. 2.2). Cells under both conditions, though, had 
similar hexosaminidase contents (Suppl. Fig. S4). 
A comparison of adherent WT and MARCKS-deficient cells in the resting state, how-
ever, did reveal a significantly different cell morphology phenotypes. As shown in Supple-
mentary Figure S7, the frequency distributions for both average cross-sectional areas and cell 
heights in living MARCKS null cells stained with the membrane dye, FM 4-64, were left-
shifted compared to WT cells, indicating decreased cell volumes for MARCKS null cells. 
These results were confirmed using phalloidin to label cortical actin filaments. Both methods 
suggested an approximately 30% decrease in cell volume for MARCKS-deficient cells com-
pared to WT (Suppl. Fig. S7-S8).
Modulation of mast cell regulated exocytosis induced by MARCKS-deficiency 
After adherence to fibronectin, WT and MARCKS null cells showed clearly different 
responses to activation by DNP: the MARCKS null cells responded more vigorously than WT 
cells at every DNP concentration tested (Fig. 2.3A). Although the differences were not statisti-
cally significant at three of the five DNP concentrations tested, at the peak of the response (3 
ng/mL) the MARCKS null cells secreted 34 +/-5% more hexosaminidase than WT. This dif-
ferential is of a magnitude which could well be significant pathologically (see Discussion). The 
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Figure 2.4:  MRP-deficiency is similar to WT secretory behavior
Adherent WT (+/+) and MRP-deficient (– / –) mast cells were tested for their respective anti-
gen-stimulated responsivity. No differences were detected between WT (filled) (n=4) and MRP 
null (open) (n=3) mast cells. The dose response curve demonstrates the b-hexosaminidase re-
lease in response to each DNP-BSA concentration through the tyrosine kinase FceRI-mediated 
pathway. Once more, the peak stimulatory response for WT and MRP-deficient cells was at 
the antigen concentration of 3 ng/mL of DNP-BSA. The WT and MRP null mast cells derived 
from embryos of the same litter were isolated from mice kindly provided by Dr. Perry Black-
shear at the National Institute of Environmental Health Sciences and allowed to adhere to 
fibronectin for 24 hours prior to DNP stimulation.
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Figure 2.5:  MARCKS-deficiency accelerates the rate of regulated exocytic release
The time course of hexosaminidase release from WT and MARCKS-deficient eHMCs adhered 
to fibronectin for 24 hours before the cells were activated with 3 ng/mL  DNP-BSA at various time 
periods prior to the full thirty minute incubation period. MARCKS-deficient eHMCs demon-
strated an enhanced release of hexosaminidase within the first two minutes compared to WT 
release (n=6 null embryos, n=10 WT embryos). Each time point value represents the amount of 
hexosaminidase released at that time point normalized to the total amount of hexosaminidase 
released during the full thirty minute incubation period. * p<0.05 
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enhancement of secretion seen with 24 hours of fibronectin adherence after stimulation with 
3 ng/mL of DNP was also observed with cells stimulated after 96 hours of fibronectin adher-
ence (Suppl. Fig. S9). However, the total cellular content of hexosaminidase remained similar 
between WT and MARCKS-deficient cells in every experiment (Fig. 2.3B), suggesting that 
MARCKS-deficiency is modulating the magnitude of regulated exocytic cargo released, not 
the amount exocytic cargo contained within the cells (Fig. 2.3A). 
MRP-deficiency does not modulate mast cell regulated exocytosis
To determine if the potentiation of mast cell regulated exocytosis resulting from 
MARCKS-deficiency was a MARCKS-specific function, the effect of MRP-deficiency was 
tested. MRP null mice are also perinatally lethal due to abnormal neuronal development, there-
fore, MRP-deficient and WT littermate eHMCs were derived from embryos provided by Dr. 
Perry Blackshear, NIEHS, and their secretory responses compared. The results indicated that 
DNP induced essentially identical responses (Fig. 2.4); hence, the role of MARCKS in regu-
lated exocytosis appears to be distinct.
MARCKS alters the kinetics of release for regulated exocytic SG cargo.
In the above experiments, the amount of regulated exocytosis was assayed after an incu-
bation period with DNP-BSA for 30 minutes, a long enough time period to complete the regu-
lated exocytic process and exhibited a significantly increased amount of regulated exocytosis in 
MARCKS null cells compared to WT cells. Next, we examined whether the kinetics of cargo re-
lease were affected by MARCKS-deficiency. We measured the amount of regulated exocytosis in 
WT and MARCKS-deficient eHMCs at different time points beginning thirty seconds after DNP 
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addition. At earlier time points (30 seconds–2 minutes), MARCKS-deficiency resulted in the 
release of more secretory cargo compared to WT eHMCs (Fig. 2.5). At five minutes, the secre-
tory responses of WT and MARCKS null eHMCs were similar, with cells already releasing 
approximately 80% of the total amount released during the thirty minute incubation. Taking 
the thirty minute time point (WT=37.28 +/- 2.90 versus null 47.52+/- 5.12% of total hexosa-
minidase released) as a complete response, the t1/2 for SG content release for WT cells was 2.35 
+/- 0.26 minutes compared to the quicker t1/2 of 0.98 +/- 0.15 minutes in MARCKS null mast 
cells. 
It is important to note, however, that despite the difference in the kinetics of the se-
cretory responses between WT and MARCKS-deficient eHMCs, in these studies no signifi-
cant difference was found between the magnitude of the responses at thirty minutes between 
MARCKS null and WT cells (0.08 > p > 0.05). This apparent lack of difference in the amount 
of secretion, which is in contrast to Fig. 2.3, likely resulted from a relatively small sample size, 
as illustrated by analysis of the original thirty minute data set presented in the Appendix.
MARCKS peptides do not demonstrate a MARCKS-specific effect in mast cells.
An experimental perturbation to test the role of MARCKS in secretion, one used with 
increasing frequency, is an exposure of WT cells to a myristoylated, 24-residue N-terminal 
MANS peptide, or a randomized control (RNS) peptide (Li, et al., 2004; Singer, et al., 2004; 
Takashi, et al., 2006). Inhibition by the MANS peptide is taken to indicate competitive interac-
tion between the peptide and native MARCKS for intracellular binding sites (Li, et al., 2004; 
Singer, et al., 2004). To address the apparent contradiction between the results of studies using 
the MANS peptide, indicating significant inhibition, and our observations indicating a non-
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essential role for MARCKS in mast cell secretion, we tested the effects of the MANS and RNS 
peptides on the secretory responses of WT and MARCKS-deficient eHMCs. Additionally, we 
tested a non-myristoylated MANS (NONG) peptide that lacked the N-terminal Glycine neces-
sary for myristoylation, and, therefore, the ability to permeate the PM. 
The MANS peptide, as previously reported for other cell types, significantly inhib-
ited regulated exocytosis in eHMCS at each dose tested (Fig. 2.6). However, MARCKS null 
eHMCs exhibited a similar inhibition by the MANS peptide as WT eHMCs, suggesting that 
the mechanism of inhibition was not MARCKS-specific. Interestingly, pretreatment with the 
RNS peptide caused inhibition of WT and MARCKS null eHMC regulated exocytosis com-
pared to untreated controls at the highest concentration tested but not the lower concentration 
(Fig. 2.6). When WT and MARCKS-deficient eHMCs were pretreated with the non-myris-
toylated NONG peptide, eHMC secretion was inhibited even more effectively than the inhibi-
tion with the MANS peptide. Pretreatment with the highest concentration of NONG peptide 
almost completely abolished the secretory response in both mast cell genotypes. These results 
suggest an extracellular, non-specific mechanism for MANS peptide inhibition of mast cell 
regulated exocytosis.
58
Figure 2.6:  MANS peptide is not MARCKS-specific in mast cells 
WT and MARCKS-deficient eHMCs were pretreated with either the MANS, RNS or NONG 
peptide, at the specified concentrations, fifteen minutes prior to FceRI stimulation demonstrat-
ed similar effects between WT (filled) and MARCKS-deficient cells (open).
WT and MARCKS null cells were pretreated with the RNS peptide (circles) at various con-
centrations. While no difference was detected between the genotypes, both demonstrated an 
increased percent of inhibition at the largest peptide concentration. MANS peptide (triangles) 
also inhibited both WT and MARCKS-deficient cells equally. The NONG peptide (squares) 
revealed similar responsivity between both genotypes. However, the NONG peptide almost 
completely inhibited regulated exocytosis at the highest peptide concentration. The amount of 
inhibition was calculated as the % of hexosaminidase release in cells untreated with peptides 
compared to cells treated with peptides. 
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DISCUSSION
Mast cells, key immune cells in the inflammatory response, have been linked to multiple 
pathologies including airway inflammation (Bradding, et al., 2006; Kalin, et al., 2008), skin 
vasculitis (Sanchez-Mejorada & Rosales, 1998; Watanabe et al., 1999; Baumann et al., 2001; 
Dugina, et al., 2003; Tam, et al., 2004), and cardiac hypertension and hypertrophy (Shiota, et 
al., 2003; Balakumar, et al., 2007; Gonzalo, et al., 2007). All of these functions depend on the 
ability of mast cells to release pro-inflammatory mediators and enzymes into the extracellular 
environment, principally through regulated exocytosis, in response to pathogens and immune 
challenge (Watanabe, et al., 1999; Baumann, et al., 2001; Balakumar, et al., 2007; Bischoff 
& Kramer, 2007; Metz & Maurer, 2007). Regulated secretion of pro-inflammatory mediators 
such as TNF-α, interleukins, lipid mediators, tryptase, chymase, serotonin and histamine from 
mast cells results in polymorphonuclear (PMN) chemotaxis and activation of other immune 
cells, leading to significant tissue damage when chronic inflammation occurs (Metcalfe, 2008). 
Understanding the regulated secretory pathway, a critical aspect of mast cell function, could be 
important for the development of future therapeutic targets in multiple diseases.
Previous peptide and siRNA studies in several types of secretory cells have indicated 
that the ubiquitously expressed MARCKS protein may serve a crucial, positive regulatory role 
in regulated exocytosis in secretory cells (Elzagallaai, et al., 2000; Rose, et al., 2001; Jerdeva, 
et al., 2005; Park, et al., 2006; Doreian, et al., 2009). A major obstacle, however, of these ap-
proaches to cell perturbation is the possibility of non-specific effects. For peptides, it is also 
the possibility of competition with MRP or other polybasic domain proteins, and other PKC 
substrates (Aderem, 1995; Matsuoka & Bennett, 2000; Streb & Miano, 2005). Gene knock-
down by siRNAs, similarly, can have unintended effects on the expression of other genes by 
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interfering with the cell’s RNA processing machinery, and siRNA knockdown often lacks good 
controls against non-specific inhibition. Embryonic mast cells provide the advantage of allow-
ing isolation of both WT and MARCKS-deficient cells on the same genetic background. Addi-
tionally, MARCKS expression is upregulated in immune cells primed by inflammatory stimuli 
(Rose, et al., 1996; Thelen, et al., 1990; Yokoyama, et al., 1998; Chun, et al., 2009), similar to 
the process of passive sensitization utilized for FceRI-mediated mast cell activation. FceRI, a 
high-affinity IgE receptor, is an essential component of allergic inflammation which activates 
mast cells only after they are first sensitized with IgE, a process which primes the cells by 
increasing cell surface expression of the receptor and crosslinks these surface receptors so that 
subsequent IgE challenge leads to activation of FceRI (Thelen, et al., 1990; Aderem, 1992; 
Rose, et al., 1996; Chun, et al., 2009). Once activated, the well-characterized receptor-mediat-
ed pathway initiates the release of pre-formed pro-inflammatory mediators through regulated 
exocytosis and induces de novo production of other pro-inflammatory cytokines (Hata, et al., 
1998; Sanchez-Mejorada & Rosales, 1998; Peng & Beaven, 2005; Rivera & Gilfillan, 2006). 
BMMCs studies stimulating the cells in suspension, an assay commonly used in the 
field, led us to first test eHMCs in suspension by comparing the magnitude of the secretory 
response from WT and MARCKS-deficient eHMCs stimulated via FceRI. WT and MARCKS 
null cells tested under these suspension conditions showed no significant difference in the 
amount of regulated exocytosis at five different DNP concentrations (Suppl. Fig. S5). The dose 
response curve, similar to previously published data, exhibited an increase in the secretory re-
sponse of both genotypes up to approximately 10 ng/mL DNP, while the two doses higher than 
10 ng/mL correlated with a dose-dependent decrease in the secretory response. These results 
suggested that MARCKS was not essential for regulated exocytosis in mast cells. 
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Earlier studies also tested mast cells under adherent conditions and showed that 
mature mast cells, in vivo, display increased sensitivity and responsiveness to immune chal-
lenge due to cell adherence to the extracellular matrix of resident tissue (Vuori & Ruosahlti, 
1993; Columbo, et al., 1995; Kruger-Krasagakes, et al., 1999). Fibronectin, specifically, has 
been shown in several previous studies to potentiate secretion in mast cells (Vuori & Ruosahlti, 
1993; Columbo, et al., 1995; Kruger-Krasagakes, et al., 1999) We confirmed this enhanced 
sensitivity to immune challenge in vitro by comparing WT eHMC secretory responses in cells 
adherent to fibronectin and cells in suspension: adherent WT cells demonstrated a three-fold 
increase in the amount of secretion, relative to cells in suspension (Fig. 2.2). 
Based on these observations, the necessity of MARCKS for regulated exocytosis un-
der adherent conditions was tested. WT and MARCKS null eHMCs activated with the same 
five DNP doses, after overnight adherence to fibronectin, revealed some surprising results. 
DNP elicited greater secretory responses from MARCKS-deficient cells at every concentra-
tion tested; these differences were statistically significant at 3 and 30 ng/mL, highly so at the 
peak response (3 ng/mL) (Fig. 2.3). At this maximal stimulation, the secretory response of 
adherent MARCKS-deficient mast cells was increased approximately one-third relative to the 
amount of WT release. Even when eHMCs were allowed to adhere to fibronectin for four days, 
MARCKS null cells still exhibited a potentiated amount of regulated secretion at the maximal 
dose, with an approximately one-fifth increase in the amount of secretory release compared to 
WT cells (n=3) (Suppl. Fig. S9). 
However, this modulatory effect of MARCKS-deficiency on the magnitude of the regu-
lated secretory response was much less potent than the effect of MARCKS-deficiency on the 
time course of release (Fig. 2.5). The absence of MARCKS significantly accelerated the rate 
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of release for secretory cargo by approximately 2.4 fold, inducing release of half of the total 
regulated exocytic cargo in approximately one minute, versus approximately 2.4 minutes in 
WT. These results suggest a role for MARCKS in the initial events of regulated exocytosis in 
modulating early events during activation of the pathway. Another study linked the transloca-
tion of MARCKS to the rapid and early release of adrenocorticotropin, rather than association 
with the slower, sustained release found in the later time period (Liu, et al., 1994), an observa-
tion that correlatively suggested a role for MARCKS in the initial kinetics of cargo release. Our 
results causally support this modulatory role for MARCKS in the rate of release for mast cells, 
since cells lacking MARCKS are capable of immediately initiating exocytic release, without 
the activation barrier seen in WT cells. 
As noted in Results, there was no significant difference in the secretory responses of 
WT and MARCKS-deficient eHMCs at the thirty minute incubation point in these studies 
(WT=37.28 +/- 2.90 versus null=47.52 +/- 5.12% of total hexosaminidase released), in con-
trast to the original observation of an approximately 34% increase in null cell secretory re-
sponse compared to WT (Fig. 2.3). Likely, the lack of statistical significance is due to a smaller 
sample size (n=6 for MARCKS null for Fig. 2.5 versus n=16 in Fig. 2.3). To test this possibility 
we systematically computed all possible 8,008 combinations of the 16 data points, taken six at 
a time, for WT and MARCKS-deficient cells, examining each smaller data subset for statisti-
cal significance using the student’s two-tailed t-test (Appendix A). The results indicated that 
49.8% of the WT versus MARCKS null secretion data subsets failed to achieve a statistically 
significant level of p<0.05. 
Next, to confirm that the regulatory function for MARCKS in mast cells is specific to 
MARCKS, the second family member, MRP, present in both WT and MARCKS-deficient cells 
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Figure 2.8:  Increased SG density-mediated model for the MARCKS-deficient increase 
in regulated exocytosis. Cell morphology studies of adherent WT and MARCKS-deficient 
eHMCs revealed significantly smaller MARCKS null cells compared to WT cells. With the 
same amount of secretory content, these conditions would result in more densely packed SGs 
with a reduced amount of SG trafficking required prior to membrane fusion events. SGs would 
then be released more quickly compared to WT SG release due to this closer proximity of the 
SGs to the PM. 
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(Fig. 2.1) was tested. MRP null cells completely mimicked WT secretory behavior (Fig. 2.4). 
The MARCKS and MRP double null mouse, unfortunately, is embryonically lethal, with the 
embryos succumbing prior to the development of mast cell progenitor cells, so eHMCs could 
not be obtained from the double null mice (personal communication, DJ Stumpo and PS Black-
shear). Notably, the lack of the MARCKS null phenotype in adherent MRP-deficient eHMCs 
(Fig. 2.4) supports the idea of a MARCKS-specific regulatory function in mast cell regulated 
exocytosis. 
Thus, these FceRI-mediated secretion studies demonstrated two observations. First, the 
presence of MARCKS is not essential for mast cell regulated exocytosis. Second, in contrast 
to reports from previous studies, MARCKS negatively regulates mast cell secretion, likely 
through modulation of the rate of release, possibly a cell-specific function. 
Inhibitiory Peptides
A synthetic myristoylated peptide representing the N-terminal 24-residues of the 
MARCKS protein has been shown to inhibit secretion in human airway goblet cells, isolated 
human neutrophils, and eisonophil-like, monocyte/macrophage and natural killer cell lines 
(Li, et al., 2001; Singer, et al., 2004; Takashi, et al., 2006). Consistent with our finding that 
MARCKS is not essential for regulated mast cell secretion, we found that the inhibition effect-
ed by the MANS peptide is not dependent on the expression of MARCKS (Fig. 2.6): both WT 
and MARCKS null cells exhibited similar responsivity to the peptide. Additional observations 
supported this finding. First, the highest concentration (100 mM) tested of the RNS peptide, 
the randomized peptide, also had a significant inhibitory effect, suggesting inhibition is at least 
partially independent of peptide sequence. Second, and more significant, the NONG peptide, a 
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non-myristoylated peptide unable to permeate the PM, had an even greater inhibition than the 
MANS peptide in both WT and MARCKS null cells. This result clearly indicates that the site 
of inhibition is on the cell surface of mast cells. Additionally, the almost complete abolishment 
of mast cell secretion suggests that the NONG peptide could potentially be an even more ef-
fective therapeutic inhibitor of secretion, despite a non-specific mode of action, if it were also 
found to be non-toxic and lack other deleterious side effects. Overall, though, our results indi-
cate that the implicated mechanism of the MANS peptide for inhibiting mast cell secretion is 
non-specific, and may be due to an electrostatic interaction that does not require entrance into 
the cell or MARCKS expression.
Inflammation and Pathology
Activation of mast cells in the respiratory system leads to a hypersensitivity response 
and PMN infiltration, causing airway obstruction and tissue damage (Prussin & Metcalfe, 
2003; Metz and Maurer, 2007). Researchers have demonstrated PMN chemotaxis from the 
blood to be a largely mast cell-mediated process (Baumann, et al., 2001; Bradding, et al., 
2006; Gonzalo, et al., 2007; Kalin, et al., 2008; Ryzhov, et al., 2008). Since mast cells are 
critical promoters of the chemotactic process, even the small one-third increase in mediator 
release in MARCKS null cells could significantly enhance the amount of PMN infiltration and 
subsequent airway obstruction and tissue damage during an inflammatory response. Addition-
ally, because mast cells are preferentially localized so their contents can be released near blood 
vessels, the effect of the accelerated amount of release in a shorter time period, as observed in 
MARCKS null cells, could also potentiate significantly the amount of PMN infiltration. One 
study found that an approximately 50% enhancement in the FceRI-mediated degranulation of 
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mouse-derived BMMCs, owing to deletion of the protein, RabGEF1, correlated with increased 
mortality, chronic and severe skin inflammation and significantly increased serum concen-
trations of histamine and IgE (Tam, et al., 2004). Though these results were derived from a 
mouse where RabGEF1 was knocked out in all cell types, the severe inflammation pathology 
observed clearly indicates the pronounced effects that can result from increased mast cell regu-
lated exocytosis.
Mechanism of Action
In aggregate, our studies suggest that MARCKS is not essential for regulated secretion, 
at least in mast cells. Rather, if the protein participates directly in the regulation of the exo-
cytic mechanism, it is as a negative modulator. This possibility is in accordance with a long- 
standing hypothesis that MARCKS stabilizes cortical actin filaments in pre-activated cells 
(Trifaro, et al., 2000; Rose, et al., 2001). This hypothesis for a MARCKS-mediated actin 
barrier disruption postulates that phosphorylation of MARCKS by PKC, which induces its 
translocation from the PM to the cytosol, directly or indirectly regulates cortical actin destabi-
lization and subsequently allows secretory granules to be trafficked to and fuse with the PM to 
undergo exocytosis (Arbuzova, et al., 2002; Ehre, et al., 2005; Pene, et al., 2005 Jerdeva, et al., 
2005; Park, et al., 2006). The exact mechanism of how MARCKS could mediate these events 
has not yet been elucidated, but previous studies have demonstrated that MARCKS transloca-
tion correlated with shorter actin filaments or decreased cortical actin below the PM (Rose, et 
al., 2001; Salli, et al., 2003; Ehre, et al., 2005). 
Alternatively, MARCKS could be modulating regulated exocytosis indirectly by 
regulating cell shape and/ or size under adherent conditions. The altered features of resting 
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MARCKS-deficient cells, decreased cross-sectional area and cell height, and an approxi-
mately 30% cell volume decrease, support this hypothesis (Supp. Fig. S7-S8). One result of 
MARCKS-deficiency is a loss of cellular extensions and smaller cells, possibly giving rise to 
the ‘rounded’ morphology described by other researchers, (Micallef, et al., 2009; Disatnik, et 
al., 2004). Since the amount of total cellular hexosaminidase remained similar between the WT 
and MARCKS null cells, the resulting increase in granule density could cause the mast cells to 
release cargo within an abbreviated time course. (Fig. 2.7). 
In conclusion, our results suggest a negative, modulatory role for MARCKS in the 
regulated secretion of mast cells. This negative regulation is expressed primarily as accelerated 
kinetics of secretion, possibly mediated by a change in cortical actin dynamics and/or cell size.
Supplementary Data Figures for Chapter 2
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Supplemental Figure S1:  Immunohistochemical verification of pure, mature mast cell 
cultures
Introduction: Embryonic hepatic-derived mast cells were isolated from homogenized livers 
of E14-E18 embryos and cultured for 5 weeks in media supplemented with SCF and IL-3. 
Cells were assayed for maturity by the presence of the high affinity IgE receptor on the cell 
surface (See Chapter 2 Materials and Methods for detailed protocol).
(A) As a control, eHMCs adherent to fibronectin-coated glass coverslips were blocked for one 
hour with the CD32/CD16 antibody (1:50) at room temperature. Cells were then stained for 
one hour with secondary rat FITC-anti-mouse IgE antibody (1:75) without prior incubation 
for one hour with the primary DNP-IgE antibody. Cells were then fixed with 4% PFA and the 
coverslips mounted onto glass slides. The control lacked significant cell surface staining.
(B) Adherent cells were first incubated with the blocking CD32/CD16 antibody for one hour 
at room temperature, rinsed, and incubated with the primary mouse anti-DNP IgE antibody 
(1:25) for one hour. After rinsing with PBS, the secondary rat anti-mouse IgE antibody (1:75) 
was applied for one hour before cells were fixed and mounted for imaging experiments.
(C) Cells were blocked with the CD32/CD16 antibody and incubated with mouse FITC-anti-
FceRI alpha antibody (1:25) (eBiosciences) for one hour at RT. Coverslips of the adherent mast 
cells were mounted onto glass slides and imaged for cell surface expression.
Conclusions: Both staining methods, repeated in three independent experiments, confirmed 
the eHMC cultures to be >99% pure.
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Supplemental Figure S2:  Ionomycin activation of BMMCs and eHMCs
Introduction: Hematopoietic bone marrow-derived mast cells were derived from 6–12 week 
old mice and activated with the calcium ionophore, ionomycin after 5 weeks of culturing and 
maturation with SCF and IL-3. 
(A) Secretory responses of WT (+/+) BMMCs stimulated with ionomycin at varying doses 
while in suspension. Values were quantitated as the amount of b-hexosaminidase activity re-
leased into the supernatant compared to the total amount of b-hexosaminidase activity from 
both supernatant and cell lysate. The background spontaneous release (<5%) was subtracted 
from DNP-stimulated cells, to show the DNP-specific secretory response. (Error bars represent 
S.E. from three independent experiments; * p<0.05; ** p<0.01.; ***p<0.001 compared to the 
amount of spontaneous release)
(B) Secretory responses of WT (+/+) suspension eHMCs stimulated with ionomycin. Peak 
responsivity of both BMMCs and eHMCs to ionomycin was 1 mM. (Error bars represent S.E. 
from three independent experiments; ** p<0.01.; ***p<0.001 compared to the amount of 
spontaneous release)
Conclusions: Both WT BMMCs and eHMCs in suspension had similar dose-dependent re-
sponses to stimulation with ionomycin, a calcium ionophore.
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Supplemental Figure S3:  PMA enhancement of submaximal ionomycin stimulation for 
WT cells
Introduction: Mast cells treated with PMA, a DAG mimic, were activated with submaximal 
ionomycin doses after 5 weeks of culturing and maturation with SCF and IL-3. 
(A) Secretory responses of suspension BMMCs stimulated with varying doses of PMA along 
with 0.5 mM ionomycin. An maximal enhancement of approximately 2.6-fold was obtained at 
the PMA dose of 100 nM.
(B) The dose response shows the secretory behavior of suspension eHMCs stimulated with 
varying doses of PMA and 0.25 mM ionomycin. While the maximal 1.8-fold enhancement in 
eHMCs was lower than the fold change observed for BMMCs, this peak increase occurred at 
the same PMA dose of 100 nM.
Values are shown as the fold change of PMA-enhanced treatment at each dose. Secretory re-
sponses of cells stimulated with ionomycin and PMA, at each specific dose, were normalized 
to the secretory response of control cells treated only with ionomycin. (Error bars represent 
S.E. from three independent measurements; * p<0.05; ** p<0.01; *** p<0.001 compared to 
the amount of release from ionomycin only treatment)
Conclusions: WT BMMCs and eHMCs in suspension demonstrated similar dose-dependent 
responses to PMA enhancement of submaximal ionomycin stimulation.
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Supplemental Figure S4:  BMMC and eHMC Total b-Hexosaminidase Content
Introduction: The total amount of cellular hexosaminidase, quantitated as absorbance units 
(A.U.) of cleaved hexosaminidase substrate, as a measure of the total amount of hexosamini-
dase in the cell lysate and supernatant combined was compared between WT BMMCs and WT 
eHMCs under various experimental conditions. 
(A) The total cellular hexosaminidase for WT BMMCs in suspension (n=7). 
(B) The total amount of cellular hexosaminidase activity for WT adherent (n=19) and suspen-
sion (n=7) eHMCs. No significant difference in the total amount of cellular hexosaminidase 
was detected between adherent (open) and suspension (filled) eHMCs. 
Conclusions: The levels for the total amount of b-hexosaminidase content were quantitatively 
similar between WT BMMCs and WT eHMCs under any experimental conditions. These re-
sults support the validity of eHMCs as a mast cell model. 
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Supplemental Figure S5:  WT BMMC Responsivity to DNP Stimulation
Introduction: WT bone marrow-derived mast cells mast cells were activated by cross-linking 
the high-affinity IgE receptor, FceRI, with DNP after 5 weeks of culturing and maturation (See 
Materials and Methods Section for Chapter 2). 
Secretory responses of WT (+/+) BMMCs stimulated with varioius DNP doses while in sus-
pension. Mean values represent at least three independent experiments (n=7).
Conclusions: The dose-dependent response of WT BMMCs to DNP was similar to the bipha-
sic responsiveness seen in WT eHMCs (Fig. 2.2).
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Supplemental Figure S6:  DNP-stimulated regulated exocytosis of suspension eHMCs
Introduction: The amount of regulated exocytosis was compared between WT (+/+) and 
MARCKS-deficient (– / –) eHMCS utilizing the suspension secretion assay at various DNP 
doses. 
A comparison between the two genotypes (n=7) demonstrated no significant differences, even 
though the responses of the MARCKS null eHMCs were typically higher than the WT re-
sponse curve at the non-inhibitory doses. 
Conclusions: MARCKS-deficiency is not essential for mast cell regulated exocytosis and does 
not alter regulated exocytosis in eHMCs in suspension.
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Supplemental Figure S7:  Phenotypic characterization of adherent eHMCs in the resting 
state
Introduction: The phenotypes of resting WT and MARCKS null cells were compared under 
conditions of adherence to fibronectin.
Methods: Images of the x-y plane of live adherent cells labeled with FM 4-64 FX fix-
able analog were captured, using an automatic stage, moving through the z-axis at des-
ignated increments from the bottom to the top of the cell. The image series was then 
imported into Volocity v4.4 and assimilated into a 3-D image, which was used to quantitatively 
measure specific cell characteristics. 
(A) The frequency distribution for the heights of individual cells was compared between WT 
and MARCKS-deficient cells. MARCKS null cells demonstrated a left-shifted distribution, 
hence shorter cells compared to WT.
(B) The frequency distribution for the cross-sectional area was quantitated for WT and 
MARCKS-deficient cells. MARCKS null cells had a left-shifted distribution compared to their 
WT counterparts. Results are derived from three independent experiments per genotype. Each 
experiment consisted of analyzing approximately 50 cells per genotype.
Conclusions: Adherent MARCKS null cells have decreased cell heights and cross-sectional 
areas compared to adherent WT eHMCs.
83
0.0 
0.1 
0.2 
0.3 
0.4 
4 5 6 7 8 9 10 11 More 
Fr
eq
ue
nc
y 
D
is
tr
ib
ut
io
n 
of
 C
el
ls
 
Cell Height (µm) 
+/+ 
- / - 
A
B
0.0 
0.1 
0.2 
0.3 
0.4 
50 100 150 200 250 300 400 
Fr
eq
ue
nc
y 
D
is
tr
ib
ut
io
n 
of
 C
el
ls
 
Cross-Sectional Area (µm^2) 
+/+ 
- /- 
84
Supplemental Figure S8:  Further comparison of phenotypes in resting, adherent cells. 
Methods: The average cell volume of adherent mast cells was estimated by staining them with 
Alexa Fluor-594 phalloidin, which labels F-actin. Individual cell volumes were quantitated us-
ing Velocity (v.4.4 Perkin Elmer) after 3-D renders of z-stacks were generated using the Leica 
SP2 confocal microscope. Thresholding parameters were set to exclude 5% of the lowest inten-
sity voxels, to avoid measuring background fluorescence, then a confluent mask filling in areas 
of lower intensity surrounded on all sides by areas of high intensity was generated. A confluent 
mask had to be generated, since fishnet-like gaps in the F-actin staining of the cortex was pres-
ent in all cells. Results were derived from three independent experiments per genotype, with 
each experiment consisting of approximately 25 cells per genotype.
(A) The average cell volume for WT and MARCKS-deficient adherent cells, as quantitated 
by the above method of phalloidin staining. On average, MARCKS-deficient adherent cells 
demonstrated a significantly decreased cell volume compared to WT cells.
(B) The table shows the average means for WT and MARCKS-deficient adherent cells, includ-
ing the total cellular b-hexosaminidase content of the two genotypes. 
Standard error is representative of the number of cells analyzed. The p-value represents the 
significance of the difference between the genotypes; *** p<0.001.
Conclusions: While both WT and MARCKS null cells exhibited similar hexosaminidase con-
tent, a decrease in cell volume for MARCKS-deficient cells was observed compared to their 
WT counterparts.
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Cross-Sectional Area (mm2) 182 +/- 8 133 +/- 6 ***
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Supplemental Figure S9:  DNP-stimulated regulated exocytosis in eHMCs adherent for 
96 hours.
Introduction: To determine if the effects of MARCKS-deficiency on adherent mast cells 
were present even under long term incubation with fibronection, the responsivity of WT and 
MARCKS-deficient eHMCS incubated in fibronectin-coated wells for 96 hours was compared.
Methods: The secretion assay was performed in the same way, with one variation. Cells were 
left in the fibronectin-coated wells of a 96-well plate for 96 hours, which included one media 
change, prior to stimulation with 3 ng/mL DNP.
Conclusions: The extended exposure to fibronectin enhanced DNP-stimulated secretion in 
both cell types, but at 3 ng/mL regulated exocytosis from MARCKS null cells was still signifi-
cantly increased compared to WT cells. Mean values represent three independent experiments. 
*= p<0.05 
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INTRODUCTION
Understanding the subcellular behavior of MARCKS following cell activation is essen-
tial for understanding how or where MARCKS may be participating in regulated exocytosis. It 
is established that phosphorylation of MARCKS by PKC induces its movement to the cytosol 
(Ohmori, et al., 2000). What is not yet fully elucidated is which components of MARCKS 
structure regulate this characteristic change. Three evolutionarily conserved regions of se-
quence present in both members of the MARCKS gene family may be involved in MARCKS 
subcellular targeting upon PKC phosphorylation: a myristoyl moiety consensus sequence site, 
a MARCKS homology-2 (MH2) domain, and the phosphorylation site domain (PSD) (Ader-
em, 1992). Additionally, between the myristoyl consensus sequence site and the MH2 domain 
lies a conservatively substituted region, evolutionarily conserved in MARCKS across species, 
but not formally described as a domain. This region was targeted because a peptide of this 
sequence has been used to significantly inhibit regulated exocytosis, a function believed to 
require proper MARCKS targeting (Seykora, et al., 1996; Singer, et al., 2004) (Fig. 1.2). 
To determine whether these domains affect subcellular targeting, we transiently trans-
fected mutant MARCKS cDNA constructs, fused at the C-terminus to enhanced yellow fluo-
Chapter 3
MARCKS Translocation and the Necessary Conserved Sequences 
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rescent protein (eYFP), into human embryonic kidney cells (HEK293) for live cell fluorescent 
imaging. Each construct was mutated in a specific region implicated for MARCKS’s sub-
cellular targeting, and transfected cells were stimulated with PKC activators ATP or phorbol 
12-myristate 13-acetate (PMA).
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MATERIALS AND METHODS
Culturing of Human Embryonic Kidney (HEK293) Cells
Human embryonic kidney cells of low passage (<P12) number were thawed from 
-80º C stock and seeded into 60 mm plates (Corning) Cells were cultured in Dulbecco’s 
Modified Essential Medium (Gibco) supplemented with 10% FBS (Gibco). Media was 
changed every other day and passaged when approximately 60% confluence was reached. 
Site-directed Mutation and Cloning of the G2A, DMH2, PsPi MARCKS cDNA Mutants 
Mutant constructs of MARCKS were generated with the Advantage GC-2 PCR kit 
(Clontech), using human MARCKS cDNA. WT human MARCKS in the pcDNA3.1 plas-
mid, a gift from the laboratory of Wanda O’Neal (UNC-Chapel Hill), was used as a tem-
plate for the non-myristoylatable (G2A), scrambled MARCKS (SM), MH2 deletion (DMH2), 
and pseudo-phosphorylated MARCKS (PsPi) mutants. The G2A, DMH2, PsPi MARCKS 
mutants were generated by PCR using the QuikChange™ Site-Directed Mutagenesis Kit 
(Stratagene) and transformed into XL-10 Gold Supercompetent cells. The PCR prim-
ers used to generate the MARCKS mutant constructs were as follows: 5’–CAGAATTC-
CACCATGGCTGCCCAGTTC–3’ forward for G2A; 5’–AGAACTGGGCAGCCATG-
GTGGAATTCTG–3’ reverse for G2A; 5’–ATTATCCGGACACAGCCGCCTCCCCA–3’ 
forward for DMH2; 5’–GTAATCCGGAGCGGCCGCCGAGTC–3’ reverse for DMH2; 
5’–GAAGCGCTTTGACTTCAAGAAGGATTTCAAGCTG–3’ forward (1) for PsPi; 5’–
CAGCTTGAAATCCTTCTTGAAGTCAAAGCGCTT–3’ reverse (1) PsPi; 5’–CAAGCT-
GAGCGGCTTCGACTTCAAGAAGAAC–3’ forward (2) for PsPi; and 5’–GTTCTTCTT-
GAAGTCGAAGCCGCTCAGCTT–3’ reverse (2) for PsPi. The MH2 deletion mutant was 
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transformed into INV110 Competent cells (Invitrogen). The plasmids were grown up in ampi-
cillin LB and DNA isolated using the Qiaprep Miniprep Kit (Qiagen) for sequence analysis by 
the UNC Sequencing Core at UNC-Chapel Hill, NC. For each MARCKS mutant construct, at 
least ten clones were analyzed for the presence of the proper mutation(s) and reading frame. 
From the successful transformers, MARCKS was extracted with a double digest by the en-
zymes EcoRI and HindIII (New England Biolabs). The DNA band was isolated using a Qia-
prep Gel Extraction kit (Qiagen) and maxipreps of the isolated DNA were prepared using the 
Qiaprep Endo–Free Maxiprep Kit (Qiagen). The purified DNA (50 ug) was ligated into the 
pML2 retroviral vector (Clontech), and maxipreps of the full-length mutated DNA were iso-
lated for transfection experiments.
Synthesis and Cloning of the Scrambled MARCKS cDNA Mutant 
The desired scrambled sequence was synthesized using Sequenase, a modified T7 
DNA Polymerase (USB Corporation) and long oligonucleotides that serve as both primers 
and template (Moore, 2001). Primers (1 ug/uL), Sequenase (10 U), buffer and dNTP (10 mM) 
were incubated for 30 minutes at 37º C. The long oligonucleotides were 5’–TAGAATTC-
CACCATGGGTGCCCAGTTCTCCACCCCTGCGGAAGGAGCCGGGGCGGAGGT-
GAAGAGGGCG–3’ as forward primer and 5’–TTCACGTGGCCATTCTCCTGTCCGTTC-
GCTTTGGAAGGCGACGAGGCCTTAGCCTCTGCCGCCCTCTTCACCTCC–3’ as the 
reverse primer. The polymerase was then heat inactivated and the product subcloned into the 
TOPO vector using the TOPO TA cloning kit (Invitrogen) and transformed into XL–10 Gold 
Supercompetent Cells. Once sequencing and proper reading frame were confirmed, the scram-
bled region was double digested and ligated into the pML2 retroviral vector, containing the 
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remaining MARCKS sequence. Qiaprep Endo–Free Maxiprep (Qiagen) was used to isolate the 
mutated DNA for transfection. 
Live Cell Imaging of HEK293 Cells
MARCKS cDNA constructs were transfected using Fugene 6 (Roche). After 48 hours, 
cells were imaged using a Nikon TE 2000-U microscope equipped with a Yokogawa Spin-
ning Disc Confocal scanhead (CSU10) and live images were acquired with a 60X 1.4 NA oil 
objective. The Hamamatsu Orca ER camera was controlled by Simple PCI software version 
6.0 (Hamamatsu). Filter settings for FITC (excitation at 488 and emission at 525/50) were used 
to capture the eYFP fluorescence. Live cells were stimulated with various concentrations of 
ATP or phorbol 12-myristate 13-acetate (PMA), a DAG mimic (Sigma). 
Statistical Analysis
Statistical differences between the means of two groups were determined by the un-
paired two-tail student’s t-test. P values below 0.05 are regarded as statistically significant and 
are indicated by asterisks.
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Figure 3.1:  Generated MARCKS cDNA Mutants 
MARCKS cDNA mutants were generated for each potential targeting region. 
(A) Full–length and unmutated human MARCKS cDNA (WT) was fused to enhanced yellow 
fluorescent protein (eYFP) at the C-terminus. 
(B) A single point nucleotide mutation translates the glycine residue to an alanine generating 
the non-myristoylatable (G2A) mutant.
(C) The novel MH2 deletion mutant (DMH2) lacks the MH2 domain of unknown function and 
was substituted for a BspE1 restriction site. 
(D) The scrambled MARCKS mutant (SM) contains the scrambled sequence of the random 
NH2-terminal sequence (RNS) peptide from Li, et al., 2001. 
(E) The final mutant is the pseudo-phosphorylated mutant (PsPi) with the serine residues of the 
PSD mutated to aspartate, mimicking a partial phosphorylation state. 
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 (A) WT
 (B) G2A
 (C) DMH2
 (D) SM
 (E) PsPi
96
RESULTS
Live visualization of WT MARCKS Translocation
First, the translocation of WT MARCKS upon PKC phosphorylation was experimen-
tally confirmed in human embryonic kidney (HEK293) cells. After HEK293 cells were trans-
fected with the full-length WT MARCKS cDNA fused to eYFP (Fig. 3.1A), the translocation 
process was recorded in real time after addition of PKC activators (Fig. 3.2). As previously 
shown (Ohmori, et al., 2000), WT MARCKS was found primarily associated with the PM in 
resting cells. Upon stimulation with the DAG mimic, PMA, which phosphosphorylates and 
activates PKC, WT MARCKS moved to the cytosol where it associated with vesicular mem-
branes. The identity of these cytosolic vesicles remains unclear since HEK293 cells are a 
non-secretory cell line. Since PMA was never removed from the solution, MARCKS remained 
in the cytosol until the completion of a 20-minute time period. However, when the cells were 
stimulated with adenosine trisphosphate (ATP), an activator of a receptor-mediated signaling 
pathway which includes PKC activation, a transient translocation of MARCKS was induced. 
Three minutes after stimulation, a peak in the intensity changes of the PM and the cytosol oc-
curred (Fig. 3.3), reflective of the movement of MARCKS-eYFP to the cytosol. By ten min-
utes, a small amount of recovery was observed, indicating a return of MARCKS-eYFP to the 
PM. 
Non-myristoylatable MARCKS does not associate with membranes
The non-myristoylatable (G2A) MARCKS mutant (Fig. 3.1B) was generated by a 
single point nucleotide mutation in the sequence recognized for MARCKS to be co-transla-
tionally myristoylated. In resting cells, G2A was primarily localized in the cytosol in a dif-
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Figure 3.2:  Translocation of WT MARCKS After PMA stimulation
HEK293 cells were transfected with WT MARCKS labelled with eYFP. PMA mimics DAG, 
the activator of PKC, and induces the translocation of PKC to the PM, where it phosphorylates 
MARCKS. As long as PMA is present in the bath, MARCKS will continually be phosphory-
lated and translocated to the cytosol. 
(A) In unstimulated cells, MARCKS flourescence is clearly PM-associated. After addition of 
PMA, MARCKS fluorescence was found in the cytosol, not just in a diffuse pattern, but also 
associated with vesicular membranes (arrow).
(B) The fluorescent intensity of the PM and cytosol of PMA-treated cells was compared to 
the fluorescent intensity of the PM and cytosol of the same cells prior to stimulation (control). 
The intensity values were normalized to the control cells and the normalized values (absolute 
values) show the smaller amount of decrease in PM intensity compared to the large increase in 
cytosolic intensity.
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Figure 3.3:  Translocation of WT MARCKS After ATP stimulation 
ATP, an agonist for a G protein-coupled purinergic receptor, was added to HEK293 cells trans-
fected with WT MARCKS-eYFP. Unlike phorbol ester stimulation, ATP only activates a tran-
sient translocation of MARCKS. In unstimulated cells, the amount of MARCKS flourescence 
associated with the PM and the cytosol were quantified before ATP addition. These intensity 
values were normalized to be the control values (black). ATP stimulation induced a significant 
decrease in PM intensity, approximately 0.60 fold, and a corresponding significant increase in 
cytosolic intensity, by more than two-fold. Recovery of the process was marked by return to 
previous PM intensity levels, and a significant decrease in cytosolic intensity. Interestingly, 
the cytosolic intensity was further decreased compared to the control values, perhaps due to 
photobleaching.
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fuse pattern (Fig. 3.4). Additionally, the diffuse pattern did not appear to be associating with 
vesicular membranes in the cytosol, either under resting conditions or in response to PKC. 
Pseudo-phosphorylated MARCKS shows increased cytosolic localization.
The pseudo-phosphorylated (PsPi) MARCKS mutant (Fig. 3.1E) was generated by 
mutating the three serine residues, normally phosphorylated by PKC, to aspartate residues. 
Consequently, this mutant is insensitive to PKC phosphorylation and carries a partial negative 
charge. (Arbuzova et al., 2002). This results in a mutant which mimicks PKC phosphorylation 
effects, even in resting cells. In resting cells, PsPi MARCKS was found to be both PM and sig-
nificantly more cytosol-associated (Fig. 3.5, 3.8), in contrast to WT MARCKS (Fig. 3.2). After 
stimulation, the mutant localization remained unchanged, as expected, due to its insensitivity 
to PKC. 
Translocation of the novel Scrambled MARCKS mutant quantitatively mimics WT 
behavior
The two novel mutants, the scrambled MARCKS and MH2 deletion mutants (Fig. 
3.2 C–D), are based on observations from Seykora, et al., 1996. They demonstrated in vitro 
that deletion of residues 6-140, lying between the myristoyl moiety and the PSD, showed 
impairment of PKC-dependent MARCKS translocation. Another group identified six novel 
phosphorylation sites in this portion of sequence, suggesting the presence of post-translational 
regulation, a sign of significance (Taniguchi, et al., 1994). What remains to be clarified is 
by what mechanism this post-translationally regulated region is significant to the PKC-de-
pendent targeting process. This question is particularly intriguing since the original deletion 
encompassed the intermediate region of conservatively substituted sequence and the conserved 
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Figure 3.4:  Translocation of G2A MARCKS After PMA stimulation 
HEK293 cells were transfected with G2A MARCKS-eYFP and stimulated with PMA (300 
nM). In resting cells, MARCKS is localized in a diffuse cyosolic pattern. A small portion of 
MARCKS was localized to the PM (arrowheads). Addition of PMA did not result in any signif-
icant change in localization, despite obvious intracellular movement and the only change ob-
served was translocation of the small amount of PM-associated G2A MARCKS to the cytsol. 
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MH2 domain. Potential targeting defects were tested by creating two separate cDNA mutants 
for the two components of the region. 
The Scrambled MARCKS (SM) mutant targets the intermediate region of conserva-
tively substituted sequence by utilizing a scrambled sequence derived from an existing peptide 
(Li, et al., 2001). This technique allowed any non-specific electrostatic contributions to be 
preserved. The idea was derived from experiments showing that a peptide corresponding to 
this intermediate region of the MARCKS sequence reduced mucin secretion in NHBE cells, 
suggesting significance of this region in regulation of MARCKS function in exocytic secretion 
(Li, et al., 2001; Singer, et al., 2004). 
Live cell imaging experiments in HEK293 cells showed no quantitative difference be-
tween SM (Fig. 3.6) and WT MARCKS targeting. However, while the majority of cells re-
sembled WT behavior, some SM-transfected cells, as shown in Fig. 3.6, exhibited pronounced 
vesicular membrane association prior to activation, compared to similar levels of overexpres-
sion in WT control cells. 
Translocation of the novel MH2 deletion mutant mimics WT behavior
The MH2 domain, the second portion of the deleted region, has been suggested to 
play a role in targeting or regulation, but the effect of the MH2 domain alone has not been 
experimentally tested. HEK293 cells transfected with a ΔMH2 MARCKS mutant, where only 
the conserved 72 bp MH2 domain was deleted, showed no qualitative difference in targeting 
compared to WT MARCKS (Fig. 3.8). While in resting cells, ΔMH2 MARCKS was localized 
to the PM. Upon PMA-induced PKC activation, ΔMH2 translocated to the cytosol and associ-
ated with vesicular membranes, mimicking WT behavior.
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Figure 3.5:  Translocation of PsPi MARCKS After PMA stimulation. 
HEK293 cells were transfected with PsPi MARCKS-eYFP and stimulated with PMA (300 
nM). In resting cells, MARCKS is localized to both the PM (arrowheads) and the cytosol with 
vesicular membrane association (arrows). PMA stimulation did not result in any significant 
change in the PM-associated localization of the PsPi mutant or a significant change in vesicular 
membrane association. 
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DISCUSSION
First, observations from previous studies were confirmed by showing the transloca-
tion of MARCKS in a live cell system using the HEK293 cell line. Cells transfected with 
WTMARCKS clearly associated with the PM in the resting state. After being stimulated with 
either PMA, a DAG mimic (Fig. 3.2), or ATP, activating a receptor-mediated response (Fig. 
3.3), MARCKS translocated to the cytosol. Interestingly, though, cytosolic MARCKS associ-
ated with the vesicular membranes in the cytosol. This is not unexpected since previous stud-
ies have demonstrated association of MARCKS with lysosomes and possibly SGs in airway 
epithelial cells (Singer, et al., 2004; Ohmori, et al., 2000; Allen & Aderem, 1995). However, 
because HEK293 cells are not a secretory cell type, it remains unclear to what intracellular 
membranes MARCKS associates with in the cytosol. The reversible translocation upon ATP 
activation clearly demonstrated the disparity between the physiological response and pharma-
cological treatment of cell culture studies. In ATP stimulated cells, the maximal translocation 
was observed approximately three minutes after stimulation, and reversal of the process was 
found to occur by approximately ten minutes after stimulation. This translocation timing cor-
relates well with the rate of release observed in mast cells upon agonist stimulation, as quan-
titated previously in Chapter 2 (Fig. 2.5). Despite the differences of non-secretory cells versus 
secretory cells, timing for complete translocation of MARCKS to the cytosol at approximately 
three minutes correlates well with the 2.5 (+/– 0.5) minutes required for 50% of the cells total 
secretory cargo to be released from WT mast cells (see Chapter 2).
Previous observations were also confirmed in real-time for the G2A MARCKS mutant. 
Our live cell imaging confirmed previous observations from both mice and in vitro studies 
that the myristoyl moiety is necessary for membrane association (Swierczynski, et al., 1996; 
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Ohmori, et al., 2000). Membrane association both in the PM and the cytosol was lacking in 
G2A-transfected cells (Fig. 3.4). It has been demonstrated that without the myristoyl moiety, 
mice lack normal postnatal viability, suggesting a physiological importance for the membrane 
association (Swierczynski, et al., 1996) mutated in the above studies. However, the functional 
consequences on regulated exocytosis remain undetermined. 
Observations of the pseudo-phosphorylated MARCKS mutant, despite having been 
utilized by other groups, revealed surprising results. Attenuation of PM association in the PsPi 
mutant has already been eloquently demonstrated and was quantitatively shown in these stud-
ies (Fig. 3.8) (Ohmori, et al., 2000). However, in HEK293 cells the PsPi mutant still associated 
with vesicular membranes before and after PMA addition (arrows in Fig. 3.5). In the myristoyl-
electrostatic switch model proposed by Stuart McLaughlin, translocation of MARCKS to the 
cytosol is induced by addition of phosphorylation charges to the PSD, thereby inhibiting the 
electrostatic interaction between the polybasic PSD and the PM (Seykora, et al., 1996, Tzlil, 
et al., 2008). The localization pattern observed in the PsPi-transfected cells revealed another 
aspect of membrane association. Despite the obviously diminished PM association found in 
mutant cells, the principally cytosolic mutant still associated with vesicular membranes (Fig. 
3.5). These results could be unique to HEK293 cells, but they raise the possibility that associa-
tion with vesicular membranes is not mediated through the same mechanism as PM associa-
tion. Another group has proposed that MARCKS positively regulates secretion by binding to 
the membranes of SGs in mucin-secreting goblet cells. This mechanism has been proposed as a 
model by which MARCKS regulates granule trafficking (Singer, et al., 2004). PsPi MARCKS 
associating with vesicular membranes supports the concept of phosphorylated MARCKS lo-
calizing to SG membranes. Further studies, however, would be required to link observations 
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Figure 3.6:  Overall, Scrambled MARCKS demonstrates WT behavior
In resting cells, Scrambled MARCKS localizes to the PM (arrowheads) and cytosolic vesicular 
membranes (arrows). Addition of PMA resulted in a significant shift from PM to labeling with 
cytosolic vesicular membranes. The distribution in most cells before and after stimulation were 
comparable to cells infected with WT MARCKS. However, some cells overexpressing the mu-
tant showed vesicular membrane localization even prior to stimulation.
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Figure 3.7:  Deletion of the MH2 domain does not affect translocation
In both resting and stimulated cells, deletion of the MH2 domain mimicked WT behavior. 
PMA activation induced MARCKS to translocate from the PM (arrowheads) to the cytosol and 
cytosolic vesicular membranes (arrows).
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made in non-secretory cells to secretory cells 
While the remaining localization studies of the SM and DMH2 mutant constructs did 
not implicate these regions for subcellular targeting, the generation of the constructs and live 
imaging experiments were the first to clearly isolate and test the importance of the amino termi-
nus for translocation. SM-transfected cells lacked any quantitative differences in PKC-induced 
movement to the cytosol, but did qualitatively appear disparate from WT in cells expressing 
similar levels of overexpression. The difference seen in several different experiments was the 
presence of cytosolic localization found in the SM mutant cells even prior to activation. As is 
demonstrated in the representative image (Fig. 3.6), while most cells had a slight, insignificant 
increase in cytosolic association, other cells appeared to have a much more obvious non-PM 
association before PKC activation. While the significance of this occassional change in subcel-
lular behavior was intriguing, it was a question beyond the focus of this study. Cells transfected 
with the DMH2 mutant, alternatively, mirrored WT behavior before and after PKC activation, 
with strikingly similar PM localization between the MH2 mutant and WT in the resting state 
(Fig. 3.3, Fig. 3.7). 
Consequently, these studies demonstrated that the only mutations affecting the 
ability of MARCKS to associate with the PM were the lack of myristoylation and the addi-
tion of phosphorylation groups (Fig. 3.8). Association with vesicular membranes, alternatively, 
was inhibited only by myristoylation. In testing the novel mutations of deleting the conserved 
MH2 domain of unknown function, or the sequence mimicked by the MANS peptide, which 
significantly inhibits secretion (Singer, et al., 2004), we surprisingly found no quantifiable 
effect on MARCKS translocation behavior. Future studies could be greatly enhanced by utiliz-
ing full-length mutants, such as these, in determining the effect of the conserved regions of 
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Figure 3.8:  Association of MARCKS Mutants with the PM in resting cells
All of the MARCKS mutants were quantitated for their ability to bind to the PM prior to PKC 
activation. The measurements were derived from at least three independently transfected im-
aging experiments, where the mean fluorescent PM and non-nuclear cytosolic intensity were 
measured using Simple PCI software (Hamamatsu). The PM:cytosol ratio for each individual 
cell in every experiment was calculated. Compared to WT MARCKS, only the G2A and PsPi 
MARCKS mutants demonstrated a significant difference in the PM: cytosol ratio, where the 
values below 1.0 represent a greater cytosolic intensity compared to PM intensity. (Error bars 
represent S.E.; *** p<0.001)
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MARCKS on some of the proteins’ subcellular functions, such as regulated exocytosis and 
cell motility. For example, the ability of MARCKS to be phosphorylated and de-phosphor-
ylated in myoblasts was correlated with the ability of the cells to adhere using full-length 
MARCKS mutants (Disatnik, et al., 2004). Consequences for mutations of these conserved 
regions in multiple cellular functions involving MARCKS, beyond translocation behavior, 
could easily be studied utilizing these constructs.
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Chapter 4
Conclusions and Future Directions
Regulated exocytosis is an important physiological process in multiple organ systems, 
including the nervous system (Li, et al., 2005; Jacques & Abdel-Samad, 2007), circulatory 
system (Sanchez-Mejorada & Rosales, 1998; Watanabe, et al., 1999; Shiota, et al., 2003; Bur-
ley, et al., 2007) and respiratory system (Baumann, et al., 2001; Singer, et al., 2004; Davis & 
Dickey, 2008). In the respiratory system, excessive regulated exocytosis of mucin results in 
mucus-clogged airways (Singer, et al., 2004; Davis & Dickey, 2008) and eventually death by 
asphyxiation. Elucidation of how the regulatory mechanisms controlling the exocytic pathway 
could provide important insight into future therapeutic techniques for preventing patient mor-
bidity in multiple lung pathologies. One protein that has been purported to be a critical, positive 
regulator of regulated exocytosis is Myristoylated alanine-rich C kinase substrate (MARCKS) 
(Elzagallaai, et al., 2000; Rose, et al., 2001; Jerdeva, et al., 2005; Li, et al., 2005; Eliyahu, et 
al., 2006; Park, et al., 2006;  Doreian, et al., 2009). MARCKS is a ubiquitously expressed PKC 
substrate and one of the two MARCKS gene family members which share multiple conserved 
regions of sequence. While both MARCKS family proteins, MARCKS and MRP, have been 
implicated in multiple cell functions, little direct testing of  their involvement has occurred be-
cause the MARCKS and MRP null mice are perinatally lethal (Stumpo, et al., 1995; Chen, et 
al., 1996) due to severe neurological defects. We avoided this obstacle by isolating mast cells 
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from the livers of E14-E18 embryos, which were either MARCKS-deficient, MRP-deficient or 
WT, and focused on directly testing the role of  MARCKS in regulated exocytosis. 
Mast cells, however, were not just a convenient secretory cell model in which to test 
MARCKS function. Mast cells are key mediators of the physiological inflammation response 
to immune challenge or tissue damage, including pulmonary physiology. Often, mast cells are 
the initial immune cells activated, upon which they release numerous pro-inflammatory me-
diators, including chemotactic signals that promote PMN immune cell infiltration to the site 
of challenge. This role for mast cells is served through secretion of the necessary pro-inflam-
matory mediators, a process mediated by regulated exocytosis (Shiota, et al., 2003; Bischoff 
& Kramer, 2007; Metz & Maurer, 2007). By testing MARCKS in mast cells, the function of 
MARCKS in both immune cell secretion and the regulated exocytic pathway in general could 
be analyzed. 
Proceeding with these studies, the eHMC system was first confirmed as a valid secretory 
model. Immunohistochemical staining of BMMCs and eHMCs with two separate antibodies to 
the high-affinity IgE tyrosine kinase receptor, FceRI, confirmed that both culturing techniques 
yielded pure and mature mast cell populations (Suppl. Fig. S1). By comparing the responsivity 
of WT BMMCs and eHMCs to various agonists, similar secretory responses demonstrated that 
eHMCs were a viable method for testing mast cell degranulation (Suppl. Fig. S2-S4). 
With validation of eHMCs as effective mast cells, the secretory phenotypes of WT and 
MARCKS-deficient mast cells were compared after activating the FceRI-mediated pathway 
by cross-linking the receptor with DNP (Suppl. Fig. S5). The first condition tested was secre-
tion of the cells while in suspension, which is the common mast cell secretion assay. When 
tested, MARCKS-deficient cells mimicked the regulated exocytic levels of WT cells. It should 
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be noted, though, that MARCKS was not necessary for secretion, since antigen-mediated se-
cretion was still present in MARCKS null cells. This result was surprising due to previous 
implications for MARCKS function in the pathway. 
The next set of experiments, though, tested mast cells under the more physiological 
condition of adherence to a substrate, conditions that revealed different results. Most major or-
gans contain populations of resident mature mast cells, adherent to the extracellular matrix and 
primed to activate the inflammation response upon challenge (Columbo, et al., 1995; Kruger-
Krasagakes, et al., 1996;  Kruger-Krasagakes, et al., 1999) . To simulate these circumstances, 
WT and MARCKS-deficient mast cells were allowed to adhere to fibronectin for 24 hours prior 
to DNP activation of FceRI. A dose response curve showed the maximal secretory response 
occurred at 3 ng/mL of DNP (Fig. 2.3A), the DNP dose used for the remaining experiments. At 
the optimal dose, MARCKS null cells released significantly more hexosaminidase in response 
to DNP than WT cells (Fig. 2.3 A), while the total amount of secretory cargo content remained 
the same between WT and MARCKS-deficient cells (Fig. 2.3B). This secretory enhancement 
in the magnitude of release was even present when cells were allowed to adhere to fibronectin 
for an extended time period of 96 hours (Suppl. Fig. S9). Another phenotypic difference be-
tween the two populations was in the shape of the cells prior to activation (Suppl. Fig. S7, S8). 
MARCKS null cells in the resting state exhibited decreased cross-sectional areas, cell heights 
(Suppl. Fig. S7) and an approximately 30% decrease in cell volume (Suppl. Fig. S8) compared 
to their WT counterparts. Further experiments could extend these studies to determine if the 
change in cell shape persisted even after the cells were activated. For example, the morpho-
logical change in individual WT cells from the resting state to thirty minutes after activation 
was also an approximately 30% decrease in cross-sectional area (Fig. 4.1). It would be of in-
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terest to learn if the smaller MARCKS-deficient mast cells lost the same ratio of cell volume 
after stimulation.
After the magnitude of the secretory response was examined, the time course of se-
cretory cargo release was compared between WT and MARCKS null cells. MARCKS null 
cells released 50% of their total secretory cargo 2.4 times faster than WT cells (Fig. 2.5). The 
accelerated rate of release of cargo for the MARCKS-deficient eHMCs was restricted to the 
early time points, from 30 seconds up to 2 minutes after activation, upon which the disparity 
disappeared. Preliminary experiments testing if the cortical actin in WT and MARCKS null 
cells showed any significant disparity 30 seconds after pathway activation, did not demonstrate 
any noticable differences (Fig. 4.2). Further studies at other time points could lead to different 
results. 
Hence, MARCKS-deficiency affects both the magnitude and time course of 
mast cell regulated exocytosis, findings which suggest that MARCKS is not essen-
tial for exocytosis, but acts as a negative modulator. Significantly, this function indi-
cates an anti-inflammatory role for MARCKS, an important therapeutic implication by 
itself, even if these observations do not translate from mast cells into other secretory cell 
types. These secretion studies could be significantly furthered by determining the in vivo 
effect of MARCKS-deficiency on mast cell regulated exocytosis. The experiment would 
involve mast cell reconstitution studies using mast cell-deficient Wsh/Wsh mice reconsti-
tuted with either MARCKS-sufficient or MARCKS-deficient mast cells, as done for other 
regulators of mast cell secretion (Melicoff, et al., 2009). The obstacle is that MARCKS null 
mice are perinatally lethal, so first hematopoietic mast cells would have to be differenti-
ated from embryonic stem cells. Simpler experiments would be to determine if MARCKS- 
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deficiency affects any other receptor-mediated mast cell degranulation pathways, particularly 
G-protein coupled receptors which also involve PKC activation (Dugina, et al., 2003; Vines 
& Prossnitz, 2004; Rivera & Gilfillan, 2006; Hua, et al., 2007; Lattin, et al., 2007). Live cell 
imaging of both WT and MARCKS-deficient mast cells activated through the FceRI would 
allow visual confirmation of whether or not a difference in the amount of release could be 
observed at earlier time points in individual cells. These imaging experiments could be labor 
intensive due to the fact that mast cells are known for their heterologous nature at the level of 
individual cell behavior and microenvironment (Baumann, et al., 2001; Jamur, et al., 2005).  
Since the finding of MARCKS as a negative regulator was novel and indicated a pos-
sible cell-specific function for MARCKS in mast cells, previous experimental methods for 
establishing a critical, positive regulatory role for MARCKS in airway epithelia cells were 
applied to eHMCS (Li, et al., 2001; Singer, et al., 2004). The MANS peptide, acting by an un-
known mechanism, has been clearly shown to inhibit regulated exocytosis of several secretory 
cells. In eHMCS, the MANS peptide was still inhibitory, but in a non-specific manner. Both 
WT and MARCKS-deficient cells demonstrated equal inhibition of mast cell degranulation 
when the peptide was applied. The random NH2-sequence (RNS) peptide also inhibited mast 
cell secretion at the highest dose, suggesting involvement of a non-specific electrostatic inter-
action. Application of a novel non-myristoylated MANS peptide (NONG) almost obliterated 
secretion due to even higher levels of inhibition than the MANS peptide. Taken together, these 
results demonstrate the clear lack of a MARCKS-specific mechanism of action that does not 
require myristoyl-mediated cell entrance for inhibition of mast cell degranulation. However, 
a comparison between our observations and previous studies does not eliminate the possibil-
ity of a role for the peptide in inhibiting both members of the MARCKS gene family. MRP, 
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the second MARCKS family member is present in both the WT and MARCKS-deficient cells 
(Fig. 2.1). The only obstacle to this observation is the significant inhibition observed with the 
NONG peptide. If the peptide is not able to enter the cell, no effect on MARCKS or MRP 
would be observed, yet an almost complete inhibition of regulated exocytosis occurred. Future 
experiments applying the non-myristoylated MANS peptide to airway epithelial cells, would 
adequately address this conundrum.
In summary, the direct effect of MARCKS-deficiency on mast cell regulated exocyto-
sis was a significant increase in the amount of regulated exocytosis and an accelerated rate of 
release following mast cell activation. These results demonstrate a negative, modulatory role 
for MARCKS. However, since these were not mechanistic studies, multiple hypotheses can be 
derived from these observations. One possible explanation is that lack of MARCKS decreases 
cell volume, which in turn increases SG density and cell priming for regulated exocytosis. 
Cell morphology studies demonstrated a MARCKS-dependent attenuation in cell volume of 
adherent cells compared to WT cells.  Since the amount of total secretory content, measured 
as total hexosaminidase activity, was similar between WT and MARCKS null cells, the cells 
are likely to be more densely packed with the same number of pre-formed SGs. This increased 
density could lead to a closer proximity of SGs to exocytic fusion sites on the PM, decreasing 
the amount of time required for SG trafficking and accelerating the rate of release in MARCKS 
null cells compared to their WT counterparts. 
A separate possibility is that MARCKS-deficient effects in mast cells can be attributed 
to a change in the cortical actin filaments underlying the the PM. It is impossible, without fur-
ther experimentation, to determine if altered cell volume or cortical actin volume are the cause 
or the effect of one another. Either way, the change observed in the decreased cortical actin 
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Figure 4.1:  Cell shape changes in WT cells after antigen-stimulated mast cell regulated 
exocytosis.
Images of WT eHMCS adherent to fibronectin and labeled with FM 4-64 were captured in the 
x-y plane as an automatic stage stepped through the z-plane at designated increments. Thirty 
minutes after antigen stimulation with 3 ng/mL of DNP z-stacks were again captured and im-
ported into Volocity v 4.4. Once 3-D images were assimilated, cell height and cross-sectional 
area were measured for individual cells. 
Mean values of cell height, cross-sectional area, and cell volume are shown in the table. The 
p-value demonstrates the significance difference between cell morphology features before 
and after antigen stimulation. Values were derived from at least two independent experiments 
where measurements of at least 50 cells were analyzed. ***= p<0.001
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0 min 30 min p-value
Cell Height (mm) 9.6 +/- 0.2 7.6 +/- 0.2 ***
Cross-Sectional Area (mm2) 182 +/- 8 161 +/- 6 ***
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volume of MARCKS-deficient cells, could support the hypothesis that MARCKS regulates 
the cortical actin barrier. Disruption of the cortical actin barrier is one of the initial events SGs 
must overcome to reach their docking sites on the PM. If lack of MARCKS results in disrup-
tion of the actin filaments of the barrier, cells would be more primed for regulated exocytosis 
once the receptor pathway is stimulated. This situation would similar to the process that oc-
curs in neuronal secretion, where a pool of vesicles already lies near the PM and vesicles are 
partially docked with the PM even prior to activation of regulated exocytosis. Consequently, 
when the high affinity IgE receptor is activated, the result is the accelerated kinetics found in 
MARCKS-deficient mast cells. 
To follow up these studies, the focus moved from direct testing of MARCKS-deficien-
cy effects on regulated exocytosis to determining which regions of MARCKS sequence were 
necessary for MARCKS to properly translocate from the PM to the cytosol. Understanding 
the translocation of MARCKS is crucial since all hypotheses of MARCKS function revolve 
around the timing and coordination of this movement. In resting secretory cells, MARCKS 
is localized to the PM. However, MARCKS moves to the cytosol following phosphorylation 
by PKC, which is activated when the regulated exocytic pathway is initiated. The regions of 
MARCKS that were mutated were conserved sequences previously implicated as important to 
the subcellular behavior of MARCKS. While the non-myristoyalatable MARCKS and pseudo-
phosphorylated MARCKS had been generated in previous studies as full-length MARCKS or 
peptides, the MH2 deletion and scrambled MARCKS mutants were novel constructs. HEK293 
cells were transfected with these various constructs and imaged in real-time following applica-
tion of PKC activators. Either PMA, a DAG mimic, or ATP, a ligand for a receptor-mediated 
pathway were used as the PKC activators. The translocation of WT-transfected cells was cap-
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Figure 4.2:  Actin staining of WT and MARCKS-deficient mast cells before and after 
regulated exocytosis. 
The x-z planes through the center of adherent eHMCS labeled with Alexa Fluor-488-phalloidin 
were captured for individual cells. Cells were incubated overnight with IgE, then either fixed 
immediately with 4% PFA or stimulated with DNP-IgE (3 ng/mL) and fixed thirty seconds 
after stimulation. Displayed images are representative of two independent experiments with at 
least 25 cells per experiment captured.
(A) Three representative images are shown for both WT and MARCKS-deficient cells stained 
with phalloidin prior to activation. The phalloidin labeling of cells prior to activation did not 
reveal any obvious differences between the staining of WT and null cells.
(B) Three representative images are shown for WT and MARCKS-deficient cells stained with 
phalloidin thirty seconds after mast cell activation with antigen (3 ng/mL). In this brief period, 
no change in the fluidity of the phalloidin-labeling pattern was detectable in MARCKS null 
cells (n=10 cells, 2 samples), similar to WT cells (n=10 cells, 2 samples) remained unchanged. 
Further expansion of these experiments would be required to support the rate of release differ-
ences observed in Fig. 2.6. 
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tured live and demonstrated the anticipated movement from the PM to the cytosol after activa-
tion. Surprisingly, though, cytosolic MARCKS associated with vesicular membranes. Only 
a few other studies have suggested MARCKS association with membranes in the cytosol, 
but this association had not been captured in live cells . The obstacle with this finding is that 
HEK293 cells are non-secretory cells and the previous findings observed association with SGs 
in secretory cells or lysosomes. However, it remains unclear with which vesicular membranes 
MARCKS associates in HEK293 cells. 
The significance of vesicular membrane association is a much more important question 
if addressed in secretory cells where MARCKS is postulated to play an important role in regu-
lated exocytosis. If association to cytosolic membranes, such as SG membranes, is a critical 
aspect of MARCKS function in regulated exocytosis, as has been suggested by other research-
ers (Li, et al., 2001; Singer, et al., 2004), capturing the timing and localization of MARCKS 
in real time would strongly clarify any cytosolic function for MARCKS. The hypothesis for 
MARCKS currently embraced by much of the field is that MARCKS functions in regulated 
exocytosis by disrupting, through controversial mechanisms, the cortical actin filaments un-
derlying the PM, so that SGs can reach their exocytic fusion sites. This hypothesis implicates 
that the role for MARCKS is complete once phosphoMARCKS moves to the cytosol. An-
other group has suggested that MARCKS function in regulated exocytosis only begins once 
phosphoMARCKS moves to the cytosol. By this mechanism, MARCKS associates with and 
promotes SG trafficking to the PM, by enabling de novo actin synthesis around the SGs. While 
neither MARCKS function is exclusive of the other, determining the timing and localization of 
MARCKS following PKC phosphorylation could clarify if a cytosolic role for MARCKS exist 
in regulated exocytosis. 
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Important progress in understanding this observation could be made by live cell imag-
ing of secretory cells infected with a fluorescent-tagged WT MARCKS. An alternative method 
our lab begun to pursue led to the generation of genomic MARCKS-eYFP transgenic mice on 
a C57Bl/6J background driven by the endogenous MARCKS promoter. These mice have been 
backcrossed and are viable into adulthood with no obvious phenotype. Isolation of eHMCs 
from MARCKS transgenic embryos, WT for endogenous MARCKS showed a high autofluo-
rescent background with a detectable MARCKS-eYFP fluorescence. Transgenic mice hetero-
zygous for MARCKS and carriers of the MARCKS-eYFP transgene have now been bred in 
an attempt to reduce the background autofluorescence. If the breeding remains successful, 
mast cells from these mice could be utilized for parallel live cell imaging studies done on the 
HEK293 cells. Continuation of these studies could yield a way to directly address the signifi-
cance of MARCKS association with cytosolic membranes using cells containing near endog-
enous levels of MARCKS. 
In this initial study, though, once the initial observations were made in WT MARCKS-
transfected cells, HEK293 cells were then transfected with the previously tested or novel full-
length MARCKS cDNA mutant constructs and activated by PMA to yield more surprising 
results. The non-myristoylatable MARCKS mutant, as expected, demonstrated severe impair-
ment of membrane association, both PM and cytosolic vesicular membranes. Observations 
of the pseudo-phosphorylated MARCKS, a mutant partially mimicking phosphoMARCKS 
and insensitive to PKC, were not completely as predicted though. Impaired PM association, 
as expected was observed in resting cells, but cytosolic vesicular membrane association was 
not inhibited. Additionally, while the small amount of PM-associated PsPi did not translo-
cate when PKC activators were added, as expected, application of PKC activators resulted in 
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increased cytosolic vesicular membrane association. The unexpected aspect of these results 
is that MARCKS translocation is believed to occur because addition of the phosphorylation 
groups added by PKC causes loss of membrane association. Observations of PsPi MARCKS 
effectively associating with vesicular membranes in the cytosol while having impaired PM 
association, suggests two different mechanisms for MARCKS association with the PM and cy-
tosolic membranes, respectively. Studies of other cell types infected with this mutant construct 
and stimulated for PKC activation could clarify if these observations are a consistent trend.
In the next set of studies, HEK293 cells transfected with the novel MH2 deletion and 
scrambled MARCKS mutant constructs, which were surprisingly similar to WT cells. MH2 
deletion cells were clearly associated with the PM in the resting state and translocated to 
vesicular membranes following PKC activation. All of the cells imaged mimicked WT behav-
ior. Observations of SM cells could not be so easily categorized. Most SM cells mimicked WT 
behavior in every aspect of the translocation process, but some of the cells were different from 
WT cells in the resting state. As shown in Fig. 3.6, some SM cells, even with the same levels of 
overexpression as WT-transfected cells, showed an increased cytosolic localization even prior 
to PKC activation. The behavior of the mutant cells following activation, though, mimicked 
WT behavior with no aberrant characteristics. When the membrane to cytosol ratio was mea-
sured in SM cells, the average ratio was not significantly different from the WT intensity ratios. 
Therefore, no quantitative difference was detected in either mutant. 
Depite these results, the observation of MH2 domain deletion and the SM region were 
the first ever recorded. Absence of any effect on MARCKS translocation still does not elimi-
nate the possibility that these mutations could affect MARCKS function in regulated exocy-
tosis or any other cellular process. Further studies could utilize cells transfected with these 
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mutants to determine if these regions, particularly the MH2 domain of unknown function, are 
necesary for any of MARCKS functions.
Overall, the MARCKS mutation studies detailed in Chapter 3 resulted in genera-
tion of a set of MARCKS mutant constructs with possibilities for furthering multiple types 
of MARCKS studies. They demonstrated that only the myristoyl moiety was necessary for 
membrane association and that all other mutations, except for PsPi MARCKS, mimicked WT 
translocation behavior. The PsPi MARCKS study suggested some novel concepts for cytosolic 
membrane association, but further studies in other cell types would be necessary to validate 
these findings. The observation of MARCKS associating with a population of intracellular 
vesicular membranes, while surprising, will also remain a mystery until further studies can be 
conducted in other cell types.
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Appendix A
Factorial Combination Statistics
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In the experiments determining if there was a difference in the total magnitude of  
secretory response, MARCKS null cells significantly enhanced the maximal secretory re-
sponse by approximately one-third compared to the secretory responses of WT cells (n=16) 
(Fig. 2.3). However, where the time course data of Fig. 2.5 (n=6), at the thirty minute in-
cubation period, is the same as used for the experiments of Fig. 2.3 the data does not show 
a significant increase in the magnitude of secretion between MARCKS null and WT cells. 
To verify statistically that this outcome is largely attributable to a smaller number of ex-
periments, we determined the number of significant p-values for all combinations of 6 that 
could be derived from the 16 data sets in Fig. 2.3. An algorithm was written for us by Abijhit 
Gurhardaphye at Virginia Tech, which automatically created the 8,008 possible combina-
tions of six data sets and the corresponding p-value for each combination. The p-values were 
manually verified for approximately 100 of the combinations, while all 8,008 combinatiaons 
were sorted using Excel to determine how many p-values were below 0.05. From all of the 
possible combinations, 50.2% of the time an n of 6 would generate a p-value of <0.05 and 
49.8% of the time it would be >0.05. Consequently, it is not surprising that the total amount 
of secretion in the time course experiment was insignificant, while the experiments of Fig. 
2.3 were statistically significant. In fact, this analysis supports the use of a larger number of 
embryos to account for mast cell variability, and implies the subtle, inessential nature of the 
MARCKS-deficient effects on the magnitude of secretion. Included are ten out of the 174 
pages of random combinations and their corresponding p-values. The analysis also empha-
sizes that the effect of MARCKS-deficiency is on the rate of cargo release in mast cells (Fig. 
2.5) is more likely to be the primary defect, rather than the magnitude of mast cell secretion.
p-values
28.23 15.42 29.73 38.43 24.75 28.26 40.84 56.15 39.81 41.50 47.51 49.23 0.001
28.23 15.42 29.73 38.43 24.75 37.38 40.84 56.15 39.81 41.50 47.51 46.95 0.003
28.23 15.42 29.73 38.43 24.75 38.13 40.84 56.15 39.81 41.50 47.51 51.50 0.003
28.23 15.42 29.73 38.43 24.75 52.11 40.84 56.15 39.81 41.50 47.51 55.94 0.027
28.23 15.42 29.73 38.43 24.75 57.78 40.84 56.15 39.81 41.50 47.51 53.22 0.057
28.23 15.42 29.73 38.43 24.75 45.09 40.84 56.15 39.81 41.50 47.51 58.30 0.010
28.23 15.42 29.73 38.43 24.75 49.14 40.84 56.15 39.81 41.50 47.51 55.76 0.018
28.23 15.42 29.73 38.43 24.75 35.92 40.84 56.15 39.81 41.50 47.51 63.06 0.004
28.23 15.42 29.73 38.43 24.75 43.81 40.84 56.15 39.81 41.50 47.51 59.78 0.009
28.23 15.42 29.73 38.43 24.75 50.19 40.84 56.15 39.81 41.50 47.51 40.71 0.037
28.23 15.42 29.73 38.43 24.75 42.51 40.84 56.15 39.81 41.50 47.51 54.23 0.007
28.23 15.42 29.73 38.43 28.26 37.38 40.84 56.15 39.81 41.50 49.23 46.95 0.003
28.23 15.42 29.73 38.43 28.26 38.13 40.84 56.15 39.81 41.50 49.23 51.50 0.003
28.23 15.42 29.73 38.43 28.26 52.11 40.84 56.15 39.81 41.50 49.23 55.94 0.027
28.23 15.42 29.73 38.43 28.26 57.78 40.84 56.15 39.81 41.50 49.23 53.22 0.058
28.23 15.42 29.73 38.43 28.26 45.09 40.84 56.15 39.81 41.50 49.23 58.30 0.010
28.23 15.42 29.73 38.43 28.26 49.14 40.84 56.15 39.81 41.50 49.23 55.76 0.018
28.23 15.42 29.73 38.43 28.26 35.92 40.84 56.15 39.81 41.50 49.23 63.06 0.004
28.23 15.42 29.73 38.43 28.26 43.81 40.84 56.15 39.81 41.50 49.23 59.78 0.009
28.23 15.42 29.73 38.43 28.26 50.19 40.84 56.15 39.81 41.50 49.23 40.71 0.039
28.23 15.42 29.73 38.43 28.26 42.51 40.84 56.15 39.81 41.50 49.23 54.23 0.007
28.23 15.42 29.73 38.43 37.38 38.13 40.84 56.15 39.81 41.50 46.95 51.50 0.008
28.23 15.42 29.73 38.43 37.38 52.11 40.84 56.15 39.81 41.50 46.95 55.94 0.047
28.23 15.42 29.73 38.43 37.38 57.78 40.84 56.15 39.81 41.50 46.95 53.22 0.093
28.23 15.42 29.73 38.43 37.38 45.09 40.84 56.15 39.81 41.50 46.95 58.30 0.020
28.23 15.42 29.73 38.43 37.38 49.14 40.84 56.15 39.81 41.50 46.95 55.76 0.033
28.23 15.42 29.73 38.43 37.38 35.92 40.84 56.15 39.81 41.50 46.95 63.06 0.008
28.23 15.42 29.73 38.43 37.38 43.81 40.84 56.15 39.81 41.50 46.95 59.78 0.017
28.23 15.42 29.73 38.43 37.38 50.19 40.84 56.15 39.81 41.50 46.95 40.71 0.069
28.23 15.42 29.73 38.43 37.38 42.51 40.84 56.15 39.81 41.50 46.95 54.23 0.014
28.23 15.42 29.73 38.43 38.13 52.11 40.84 56.15 39.81 41.50 51.50 55.94 0.041
28.23 15.42 29.73 38.43 38.13 57.78 40.84 56.15 39.81 41.50 51.50 53.22 0.081
28.23 15.42 29.73 38.43 38.13 45.09 40.84 56.15 39.81 41.50 51.50 58.30 0.017
28.23 15.42 29.73 38.43 38.13 49.14 40.84 56.15 39.81 41.50 51.50 55.76 0.029
28.23 15.42 29.73 38.43 38.13 35.92 40.84 56.15 39.81 41.50 51.50 63.06 0.007
28.23 15.42 29.73 38.43 38.13 43.81 40.84 56.15 39.81 41.50 51.50 59.78 0.015
28.23 15.42 29.73 38.43 38.13 50.19 40.84 56.15 39.81 41.50 51.50 40.71 0.062
28.23 15.42 29.73 38.43 38.13 42.51 40.84 56.15 39.81 41.50 51.50 54.23 0.013
28.23 15.42 29.73 38.43 52.11 57.78 40.84 56.15 39.81 41.50 55.94 53.22 0.161
28.23 15.42 29.73 38.43 52.11 45.09 40.84 56.15 39.81 41.50 55.94 58.30 0.057
28.23 15.42 29.73 38.43 52.11 49.14 40.84 56.15 39.81 41.50 55.94 55.76 0.081
28.23 15.42 29.73 38.43 52.11 35.92 40.84 56.15 39.81 41.50 55.94 63.06 0.030
28.23 15.42 29.73 38.43 52.11 43.81 40.84 56.15 39.81 41.50 55.94 59.78 0.051
28.23 15.42 29.73 38.43 52.11 50.19 40.84 56.15 39.81 41.50 55.94 40.71 0.155
28.23 15.42 29.73 38.43 52.11 42.51 40.84 56.15 39.81 41.50 55.94 54.23 0.051
SET 1 SET 2
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28.23 15.42 29.73 38.43 57.78 45.09 40.84 56.15 39.81 41.50 53.22 58.30 0.101
28.23 15.42 29.73 38.43 57.78 49.14 40.84 56.15 39.81 41.50 53.22 55.76 0.136
28.23 15.42 29.73 38.43 57.78 35.92 40.84 56.15 39.81 41.50 53.22 63.06 0.059
28.23 15.42 29.73 38.43 57.78 43.81 40.84 56.15 39.81 41.50 53.22 59.78 0.092
28.23 15.42 29.73 38.43 57.78 50.19 40.84 56.15 39.81 41.50 53.22 40.71 0.240
28.23 15.42 29.73 38.43 57.78 42.51 40.84 56.15 39.81 41.50 53.22 54.23 0.096
28.23 15.42 29.73 38.43 45.09 49.14 40.84 56.15 39.81 41.50 58.30 55.76 0.043
28.23 15.42 29.73 38.43 45.09 35.92 40.84 56.15 39.81 41.50 58.30 63.06 0.013
28.23 15.42 29.73 38.43 45.09 43.81 40.84 56.15 39.81 41.50 58.30 59.78 0.025
28.23 15.42 29.73 38.43 45.09 50.19 40.84 56.15 39.81 41.50 58.30 40.71 0.090
28.23 15.42 29.73 38.43 45.09 42.51 40.84 56.15 39.81 41.50 58.30 54.23 0.024
28.23 15.42 29.73 38.43 49.14 35.92 40.84 56.15 39.81 41.50 55.76 63.06 0.022
28.23 15.42 29.73 38.43 49.14 43.81 40.84 56.15 39.81 41.50 55.76 59.78 0.038
28.23 15.42 29.73 38.43 49.14 50.19 40.84 56.15 39.81 41.50 55.76 40.71 0.126
28.23 15.42 29.73 38.43 49.14 42.51 40.84 56.15 39.81 41.50 55.76 54.23 0.038
28.23 15.42 29.73 38.43 35.92 43.81 40.84 56.15 39.81 41.50 63.06 59.78 0.012
28.23 15.42 29.73 38.43 35.92 50.19 40.84 56.15 39.81 41.50 63.06 40.71 0.049
28.23 15.42 29.73 38.43 35.92 42.51 40.84 56.15 39.81 41.50 63.06 54.23 0.011
28.23 15.42 29.73 38.43 43.81 50.19 40.84 56.15 39.81 41.50 59.78 40.71 0.081
28.23 15.42 29.73 38.43 43.81 42.51 40.84 56.15 39.81 41.50 59.78 54.23 0.021
28.23 15.42 29.73 38.43 50.19 42.51 40.84 56.15 39.81 41.50 40.71 54.23 0.080
28.23 15.42 29.73 24.75 28.26 37.38 40.84 56.15 39.81 47.51 49.23 46.95 0.000
28.23 15.42 29.73 24.75 28.26 38.13 40.84 56.15 39.81 47.51 49.23 51.50 0.000
28.23 15.42 29.73 24.75 28.26 52.11 40.84 56.15 39.81 47.51 49.23 55.94 0.009
28.23 15.42 29.73 24.75 28.26 57.78 40.84 56.15 39.81 47.51 49.23 53.22 0.023
28.23 15.42 29.73 24.75 28.26 45.09 40.84 56.15 39.81 47.51 49.23 58.30 0.002
28.23 15.42 29.73 24.75 28.26 49.14 40.84 56.15 39.81 47.51 49.23 55.76 0.005
28.23 15.42 29.73 24.75 28.26 35.92 40.84 56.15 39.81 47.51 49.23 63.06 0.001
28.23 15.42 29.73 24.75 28.26 43.81 40.84 56.15 39.81 47.51 49.23 59.78 0.002
28.23 15.42 29.73 24.75 28.26 50.19 40.84 56.15 39.81 47.51 49.23 40.71 0.012
28.23 15.42 29.73 24.75 28.26 42.51 40.84 56.15 39.81 47.51 49.23 54.23 0.001
28.23 15.42 29.73 24.75 37.38 38.13 40.84 56.15 39.81 47.51 46.95 51.50 0.002
28.23 15.42 29.73 24.75 37.38 52.11 40.84 56.15 39.81 47.51 46.95 55.94 0.018
28.23 15.42 29.73 24.75 37.38 57.78 40.84 56.15 39.81 47.51 46.95 53.22 0.040
28.23 15.42 29.73 24.75 37.38 45.09 40.84 56.15 39.81 47.51 46.95 58.30 0.006
28.23 15.42 29.73 24.75 37.38 49.14 40.84 56.15 39.81 47.51 46.95 55.76 0.011
28.23 15.42 29.73 24.75 37.38 35.92 40.84 56.15 39.81 47.51 46.95 63.06 0.002
28.23 15.42 29.73 24.75 37.38 43.81 40.84 56.15 39.81 47.51 46.95 59.78 0.005
28.23 15.42 29.73 24.75 37.38 50.19 40.84 56.15 39.81 47.51 46.95 40.71 0.025
28.23 15.42 29.73 24.75 37.38 42.51 40.84 56.15 39.81 47.51 46.95 54.23 0.004
28.23 15.42 29.73 24.75 38.13 52.11 40.84 56.15 39.81 47.51 51.50 55.94 0.015
28.23 15.42 29.73 24.75 38.13 57.78 40.84 56.15 39.81 47.51 51.50 53.22 0.035
28.23 15.42 29.73 24.75 38.13 45.09 40.84 56.15 39.81 47.51 51.50 58.30 0.005
28.23 15.42 29.73 24.75 38.13 49.14 40.84 56.15 39.81 47.51 51.50 55.76 0.010
28.23 15.42 29.73 24.75 38.13 35.92 40.84 56.15 39.81 47.51 51.50 63.06 0.002
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28.23 15.42 29.73 24.75 38.13 43.81 40.84 56.15 39.81 47.51 51.50 59.78 0.004
28.23 15.42 29.73 24.75 38.13 50.19 40.84 56.15 39.81 47.51 51.50 40.71 0.023
28.23 15.42 29.73 24.75 38.13 42.51 40.84 56.15 39.81 47.51 51.50 54.23 0.003
28.23 15.42 29.73 24.75 52.11 57.78 40.84 56.15 39.81 47.51 55.94 53.22 0.083
28.23 15.42 29.73 24.75 52.11 45.09 40.84 56.15 39.81 47.51 55.94 58.30 0.024
28.23 15.42 29.73 24.75 52.11 49.14 40.84 56.15 39.81 47.51 55.94 55.76 0.036
28.23 15.42 29.73 24.75 52.11 35.92 40.84 56.15 39.81 47.51 55.94 63.06 0.011
28.23 15.42 29.73 24.75 52.11 43.81 40.84 56.15 39.81 47.51 55.94 59.78 0.021
28.23 15.42 29.73 24.75 52.11 50.19 40.84 56.15 39.81 47.51 55.94 40.71 0.074
28.23 15.42 29.73 24.75 52.11 42.51 40.84 56.15 39.81 47.51 55.94 54.23 0.021
28.23 15.42 29.73 24.75 57.78 45.09 40.84 56.15 39.81 47.51 53.22 58.30 0.048
28.23 15.42 29.73 24.75 57.78 49.14 40.84 56.15 39.81 47.51 53.22 55.76 0.068
28.23 15.42 29.73 24.75 57.78 35.92 40.84 56.15 39.81 47.51 53.22 63.06 0.026
28.23 15.42 29.73 24.75 57.78 43.81 40.84 56.15 39.81 47.51 53.22 59.78 0.043
28.23 15.42 29.73 24.75 57.78 50.19 40.84 56.15 39.81 47.51 53.22 40.71 0.126
28.23 15.42 29.73 24.75 57.78 42.51 40.84 56.15 39.81 47.51 53.22 54.23 0.044
28.23 15.42 29.73 24.75 45.09 49.14 40.84 56.15 39.81 47.51 58.30 55.76 0.017
28.23 15.42 29.73 24.75 45.09 35.92 40.84 56.15 39.81 47.51 58.30 63.06 0.004
28.23 15.42 29.73 24.75 45.09 43.81 40.84 56.15 39.81 47.51 58.30 59.78 0.009
28.23 15.42 29.73 24.75 45.09 50.19 40.84 56.15 39.81 47.51 58.30 40.71 0.039
28.23 15.42 29.73 24.75 45.09 42.51 40.84 56.15 39.81 47.51 58.30 54.23 0.008
28.23 15.42 29.73 24.75 49.14 35.92 40.84 56.15 39.81 47.51 55.76 63.06 0.008
28.23 15.42 29.73 24.75 49.14 43.81 40.84 56.15 39.81 47.51 55.76 59.78 0.015
28.23 15.42 29.73 24.75 49.14 50.19 40.84 56.15 39.81 47.51 55.76 40.71 0.057
28.23 15.42 29.73 24.75 49.14 42.51 40.84 56.15 39.81 47.51 55.76 54.23 0.014
28.23 15.42 29.73 24.75 35.92 43.81 40.84 56.15 39.81 47.51 63.06 59.78 0.003
28.23 15.42 29.73 24.75 35.92 50.19 40.84 56.15 39.81 47.51 63.06 40.71 0.019
28.23 15.42 29.73 24.75 35.92 42.51 40.84 56.15 39.81 47.51 63.06 54.23 0.003
28.23 15.42 29.73 24.75 43.81 50.19 40.84 56.15 39.81 47.51 59.78 40.71 0.034
28.23 15.42 29.73 24.75 43.81 42.51 40.84 56.15 39.81 47.51 59.78 54.23 0.007
28.23 15.42 29.73 24.75 50.19 42.51 40.84 56.15 39.81 47.51 40.71 54.23 0.032
28.23 15.42 29.73 28.26 37.38 38.13 40.84 56.15 39.81 49.23 46.95 51.50 0.002
28.23 15.42 29.73 28.26 37.38 52.11 40.84 56.15 39.81 49.23 46.95 55.94 0.018
28.23 15.42 29.73 28.26 37.38 57.78 40.84 56.15 39.81 49.23 46.95 53.22 0.041
28.23 15.42 29.73 28.26 37.38 45.09 40.84 56.15 39.81 49.23 46.95 58.30 0.006
28.23 15.42 29.73 28.26 37.38 49.14 40.84 56.15 39.81 49.23 46.95 55.76 0.011
28.23 15.42 29.73 28.26 37.38 35.92 40.84 56.15 39.81 49.23 46.95 63.06 0.002
28.23 15.42 29.73 28.26 37.38 43.81 40.84 56.15 39.81 49.23 46.95 59.78 0.005
28.23 15.42 29.73 28.26 37.38 50.19 40.84 56.15 39.81 49.23 46.95 40.71 0.026
28.23 15.42 29.73 28.26 37.38 42.51 40.84 56.15 39.81 49.23 46.95 54.23 0.004
28.23 15.42 29.73 28.26 38.13 52.11 40.84 56.15 39.81 49.23 51.50 55.94 0.015
28.23 15.42 29.73 28.26 38.13 57.78 40.84 56.15 39.81 49.23 51.50 53.22 0.036
28.23 15.42 29.73 28.26 38.13 45.09 40.84 56.15 39.81 49.23 51.50 58.30 0.005
28.23 15.42 29.73 28.26 38.13 49.14 40.84 56.15 39.81 49.23 51.50 55.76 0.010
28.23 15.42 29.73 28.26 38.13 35.92 40.84 56.15 39.81 49.23 51.50 63.06 0.002
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28.23 15.42 29.73 28.26 38.13 43.81 40.84 56.15 39.81 49.23 51.50 59.78 0.004
28.23 15.42 29.73 28.26 38.13 50.19 40.84 56.15 39.81 49.23 51.50 40.71 0.024
28.23 15.42 29.73 28.26 38.13 42.51 40.84 56.15 39.81 49.23 51.50 54.23 0.003
28.23 15.42 29.73 28.26 52.11 57.78 40.84 56.15 39.81 49.23 55.94 53.22 0.084
28.23 15.42 29.73 28.26 52.11 45.09 40.84 56.15 39.81 49.23 55.94 58.30 0.024
28.23 15.42 29.73 28.26 52.11 49.14 40.84 56.15 39.81 49.23 55.94 55.76 0.036
28.23 15.42 29.73 28.26 52.11 35.92 40.84 56.15 39.81 49.23 55.94 63.06 0.011
28.23 15.42 29.73 28.26 52.11 43.81 40.84 56.15 39.81 49.23 55.94 59.78 0.021
28.23 15.42 29.73 28.26 52.11 50.19 40.84 56.15 39.81 49.23 55.94 40.71 0.076
28.23 15.42 29.73 28.26 52.11 42.51 40.84 56.15 39.81 49.23 55.94 54.23 0.020
28.23 15.42 29.73 28.26 57.78 45.09 40.84 56.15 39.81 49.23 53.22 58.30 0.048
28.23 15.42 29.73 28.26 57.78 49.14 40.84 56.15 39.81 49.23 53.22 55.76 0.068
28.23 15.42 29.73 28.26 57.78 35.92 40.84 56.15 39.81 49.23 53.22 63.06 0.026
28.23 15.42 29.73 28.26 57.78 43.81 40.84 56.15 39.81 49.23 53.22 59.78 0.043
28.23 15.42 29.73 28.26 57.78 50.19 40.84 56.15 39.81 49.23 53.22 40.71 0.129
28.23 15.42 29.73 28.26 57.78 42.51 40.84 56.15 39.81 49.23 53.22 54.23 0.044
28.23 15.42 29.73 28.26 45.09 49.14 40.84 56.15 39.81 49.23 58.30 55.76 0.017
28.23 15.42 29.73 28.26 45.09 35.92 40.84 56.15 39.81 49.23 58.30 63.06 0.004
28.23 15.42 29.73 28.26 45.09 43.81 40.84 56.15 39.81 49.23 58.30 59.78 0.008
28.23 15.42 29.73 28.26 45.09 50.19 40.84 56.15 39.81 49.23 58.30 40.71 0.039
28.23 15.42 29.73 28.26 45.09 42.51 40.84 56.15 39.81 49.23 58.30 54.23 0.008
28.23 15.42 29.73 28.26 49.14 35.92 40.84 56.15 39.81 49.23 55.76 63.06 0.007
28.23 15.42 29.73 28.26 49.14 43.81 40.84 56.15 39.81 49.23 55.76 59.78 0.015
28.23 15.42 29.73 28.26 49.14 50.19 40.84 56.15 39.81 49.23 55.76 40.71 0.058
28.23 15.42 29.73 28.26 49.14 42.51 40.84 56.15 39.81 49.23 55.76 54.23 0.014
28.23 15.42 29.73 28.26 35.92 43.81 40.84 56.15 39.81 49.23 63.06 59.78 0.003
28.23 15.42 29.73 28.26 35.92 50.19 40.84 56.15 39.81 49.23 63.06 40.71 0.019
28.23 15.42 29.73 28.26 35.92 42.51 40.84 56.15 39.81 49.23 63.06 54.23 0.003
28.23 15.42 29.73 28.26 43.81 50.19 40.84 56.15 39.81 49.23 59.78 40.71 0.035
28.23 15.42 29.73 28.26 43.81 42.51 40.84 56.15 39.81 49.23 59.78 54.23 0.007
28.23 15.42 29.73 28.26 50.19 42.51 40.84 56.15 39.81 49.23 40.71 54.23 0.033
28.23 15.42 29.73 37.38 38.13 52.11 40.84 56.15 39.81 46.95 51.50 55.94 0.027
28.23 15.42 29.73 37.38 38.13 57.78 40.84 56.15 39.81 46.95 51.50 53.22 0.058
28.23 15.42 29.73 37.38 38.13 45.09 40.84 56.15 39.81 46.95 51.50 58.30 0.010
28.23 15.42 29.73 37.38 38.13 49.14 40.84 56.15 39.81 46.95 51.50 55.76 0.018
28.23 15.42 29.73 37.38 38.13 35.92 40.84 56.15 39.81 46.95 51.50 63.06 0.004
28.23 15.42 29.73 37.38 38.13 43.81 40.84 56.15 39.81 46.95 51.50 59.78 0.009
28.23 15.42 29.73 37.38 38.13 50.19 40.84 56.15 39.81 46.95 51.50 40.71 0.042
28.23 15.42 29.73 37.38 38.13 42.51 40.84 56.15 39.81 46.95 51.50 54.23 0.007
28.23 15.42 29.73 37.38 52.11 57.78 40.84 56.15 39.81 46.95 55.94 53.22 0.122
28.23 15.42 29.73 37.38 52.11 45.09 40.84 56.15 39.81 46.95 55.94 58.30 0.039
28.23 15.42 29.73 37.38 52.11 49.14 40.84 56.15 39.81 46.95 55.94 55.76 0.057
28.23 15.42 29.73 37.38 52.11 35.92 40.84 56.15 39.81 46.95 55.94 63.06 0.020
28.23 15.42 29.73 37.38 52.11 43.81 40.84 56.15 39.81 46.95 55.94 59.78 0.034
28.23 15.42 29.73 37.38 52.11 50.19 40.84 56.15 39.81 46.95 55.94 40.71 0.116
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28.23 15.42 29.73 37.38 52.11 42.51 40.84 56.15 39.81 46.95 55.94 54.23 0.034
28.23 15.42 29.73 37.38 57.78 45.09 40.84 56.15 39.81 46.95 53.22 58.30 0.074
28.23 15.42 29.73 37.38 57.78 49.14 40.84 56.15 39.81 46.95 53.22 55.76 0.101
28.23 15.42 29.73 37.38 57.78 35.92 40.84 56.15 39.81 46.95 53.22 63.06 0.042
28.23 15.42 29.73 37.38 57.78 43.81 40.84 56.15 39.81 46.95 53.22 59.78 0.066
28.23 15.42 29.73 37.38 57.78 50.19 40.84 56.15 39.81 46.95 53.22 40.71 0.188
28.23 15.42 29.73 37.38 57.78 42.51 40.84 56.15 39.81 46.95 53.22 54.23 0.069
28.23 15.42 29.73 37.38 45.09 49.14 40.84 56.15 39.81 46.95 58.30 55.76 0.028
28.23 15.42 29.73 37.38 45.09 35.92 40.84 56.15 39.81 46.95 58.30 63.06 0.008
28.23 15.42 29.73 37.38 45.09 43.81 40.84 56.15 39.81 46.95 58.30 59.78 0.015
28.23 15.42 29.73 37.38 45.09 50.19 40.84 56.15 39.81 46.95 58.30 40.71 0.064
28.23 15.42 29.73 37.38 45.09 42.51 40.84 56.15 39.81 46.95 58.30 54.23 0.015
28.23 15.42 29.73 37.38 49.14 35.92 40.84 56.15 39.81 46.95 55.76 63.06 0.014
28.23 15.42 29.73 37.38 49.14 43.81 40.84 56.15 39.81 46.95 55.76 59.78 0.025
28.23 15.42 29.73 37.38 49.14 50.19 40.84 56.15 39.81 46.95 55.76 40.71 0.092
28.23 15.42 29.73 37.38 49.14 42.51 40.84 56.15 39.81 46.95 55.76 54.23 0.024
28.23 15.42 29.73 37.38 35.92 43.81 40.84 56.15 39.81 46.95 63.06 59.78 0.007
28.23 15.42 29.73 37.38 35.92 50.19 40.84 56.15 39.81 46.95 63.06 40.71 0.034
28.23 15.42 29.73 37.38 35.92 42.51 40.84 56.15 39.81 46.95 63.06 54.23 0.006
28.23 15.42 29.73 37.38 43.81 50.19 40.84 56.15 39.81 46.95 59.78 40.71 0.057
28.23 15.42 29.73 37.38 43.81 42.51 40.84 56.15 39.81 46.95 59.78 54.23 0.013
28.23 15.42 29.73 37.38 50.19 42.51 40.84 56.15 39.81 46.95 40.71 54.23 0.056
28.23 15.42 29.73 38.13 52.11 57.78 40.84 56.15 39.81 51.50 55.94 53.22 0.106
28.23 15.42 29.73 38.13 52.11 45.09 40.84 56.15 39.81 51.50 55.94 58.30 0.032
28.23 15.42 29.73 38.13 52.11 49.14 40.84 56.15 39.81 51.50 55.94 55.76 0.048
28.23 15.42 29.73 38.13 52.11 35.92 40.84 56.15 39.81 51.50 55.94 63.06 0.016
28.23 15.42 29.73 38.13 52.11 43.81 40.84 56.15 39.81 51.50 55.94 59.78 0.029
28.23 15.42 29.73 38.13 52.11 50.19 40.84 56.15 39.81 51.50 55.94 40.71 0.102
28.23 15.42 29.73 38.13 52.11 42.51 40.84 56.15 39.81 51.50 55.94 54.23 0.029
28.23 15.42 29.73 38.13 57.78 45.09 40.84 56.15 39.81 51.50 53.22 58.30 0.063
28.23 15.42 29.73 38.13 57.78 49.14 40.84 56.15 39.81 51.50 53.22 55.76 0.087
28.23 15.42 29.73 38.13 57.78 35.92 40.84 56.15 39.81 51.50 53.22 63.06 0.035
28.23 15.42 29.73 38.13 57.78 43.81 40.84 56.15 39.81 51.50 53.22 59.78 0.057
28.23 15.42 29.73 38.13 57.78 50.19 40.84 56.15 39.81 51.50 53.22 40.71 0.166
28.23 15.42 29.73 38.13 57.78 42.51 40.84 56.15 39.81 51.50 53.22 54.23 0.059
28.23 15.42 29.73 38.13 45.09 49.14 40.84 56.15 39.81 51.50 58.30 55.76 0.024
28.23 15.42 29.73 38.13 45.09 35.92 40.84 56.15 39.81 51.50 58.30 63.06 0.006
28.23 15.42 29.73 38.13 45.09 43.81 40.84 56.15 39.81 51.50 58.30 59.78 0.013
28.23 15.42 29.73 38.13 45.09 50.19 40.84 56.15 39.81 51.50 58.30 40.71 0.056
28.23 15.42 29.73 38.13 45.09 42.51 40.84 56.15 39.81 51.50 58.30 54.23 0.012
28.23 15.42 29.73 38.13 49.14 35.92 40.84 56.15 39.81 51.50 55.76 63.06 0.011
28.23 15.42 29.73 38.13 49.14 43.81 40.84 56.15 39.81 51.50 55.76 59.78 0.021
28.23 15.42 29.73 38.13 49.14 50.19 40.84 56.15 39.81 51.50 55.76 40.71 0.081
28.23 15.42 29.73 38.13 49.14 42.51 40.84 56.15 39.81 51.50 55.76 54.23 0.020
28.23 15.42 29.73 38.13 35.92 43.81 40.84 56.15 39.81 51.50 63.06 59.78 0.005
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p-valuesSET 1 SET 2
28.23 15.42 29.73 38.13 35.92 50.19 40.84 56.15 39.81 51.50 63.06 40.71 0.029
28.23 15.42 29.73 38.13 35.92 42.51 40.84 56.15 39.81 51.50 63.06 54.23 0.005
28.23 15.42 29.73 38.13 43.81 50.19 40.84 56.15 39.81 51.50 59.78 40.71 0.050
28.23 15.42 29.73 38.13 43.81 42.51 40.84 56.15 39.81 51.50 59.78 54.23 0.010
28.23 15.42 29.73 38.13 50.19 42.51 40.84 56.15 39.81 51.50 40.71 54.23 0.049
28.23 15.42 29.73 52.11 57.78 45.09 40.84 56.15 39.81 55.94 53.22 58.30 0.119
28.23 15.42 29.73 52.11 57.78 49.14 40.84 56.15 39.81 55.94 53.22 55.76 0.155
28.23 15.42 29.73 52.11 57.78 35.92 40.84 56.15 39.81 55.94 53.22 63.06 0.074
28.23 15.42 29.73 52.11 57.78 43.81 40.84 56.15 39.81 55.94 53.22 59.78 0.108
28.23 15.42 29.73 52.11 57.78 50.19 40.84 56.15 39.81 55.94 53.22 40.71 0.271
28.23 15.42 29.73 52.11 57.78 42.51 40.84 56.15 39.81 55.94 53.22 54.23 0.118
28.23 15.42 29.73 52.11 45.09 49.14 40.84 56.15 39.81 55.94 58.30 55.76 0.059
28.23 15.42 29.73 52.11 45.09 35.92 40.84 56.15 39.81 55.94 58.30 63.06 0.022
28.23 15.42 29.73 52.11 45.09 43.81 40.84 56.15 39.81 55.94 58.30 59.78 0.037
28.23 15.42 29.73 52.11 45.09 50.19 40.84 56.15 39.81 55.94 58.30 40.71 0.122
28.23 15.42 29.73 52.11 45.09 42.51 40.84 56.15 39.81 55.94 58.30 54.23 0.039
28.23 15.42 29.73 52.11 49.14 35.92 40.84 56.15 39.81 55.94 55.76 63.06 0.033
28.23 15.42 29.73 52.11 49.14 43.81 40.84 56.15 39.81 55.94 55.76 59.78 0.053
28.23 15.42 29.73 52.11 49.14 50.19 40.84 56.15 39.81 55.94 55.76 40.71 0.161
28.23 15.42 29.73 52.11 49.14 42.51 40.84 56.15 39.81 55.94 55.76 54.23 0.056
28.23 15.42 29.73 52.11 35.92 43.81 40.84 56.15 39.81 55.94 63.06 59.78 0.019
28.23 15.42 29.73 52.11 35.92 50.19 40.84 56.15 39.81 55.94 63.06 40.71 0.073
28.23 15.42 29.73 52.11 35.92 42.51 40.84 56.15 39.81 55.94 63.06 54.23 0.020
28.23 15.42 29.73 52.11 43.81 50.19 40.84 56.15 39.81 55.94 59.78 40.71 0.111
28.23 15.42 29.73 52.11 43.81 42.51 40.84 56.15 39.81 55.94 59.78 54.23 0.034
28.23 15.42 29.73 52.11 50.19 42.51 40.84 56.15 39.81 55.94 40.71 54.23 0.117
28.23 15.42 29.73 57.78 45.09 49.14 40.84 56.15 39.81 53.22 58.30 55.76 0.100
28.23 15.42 29.73 57.78 45.09 35.92 40.84 56.15 39.81 53.22 58.30 63.06 0.043
28.23 15.42 29.73 57.78 45.09 43.81 40.84 56.15 39.81 53.22 58.30 59.78 0.067
28.23 15.42 29.73 57.78 45.09 50.19 40.84 56.15 39.81 53.22 58.30 40.71 0.188
28.23 15.42 29.73 57.78 45.09 42.51 40.84 56.15 39.81 53.22 58.30 54.23 0.072
28.23 15.42 29.73 57.78 49.14 35.92 40.84 56.15 39.81 53.22 55.76 63.06 0.060
28.23 15.42 29.73 57.78 49.14 43.81 40.84 56.15 39.81 53.22 55.76 59.78 0.091
28.23 15.42 29.73 57.78 49.14 50.19 40.84 56.15 39.81 53.22 55.76 40.71 0.238
28.23 15.42 29.73 57.78 49.14 42.51 40.84 56.15 39.81 53.22 55.76 54.23 0.098
28.23 15.42 29.73 57.78 35.92 43.81 40.84 56.15 39.81 53.22 63.06 59.78 0.039
28.23 15.42 29.73 57.78 35.92 50.19 40.84 56.15 39.81 53.22 63.06 40.71 0.120
28.23 15.42 29.73 57.78 35.92 42.51 40.84 56.15 39.81 53.22 63.06 54.23 0.041
28.23 15.42 29.73 57.78 43.81 50.19 40.84 56.15 39.81 53.22 59.78 40.71 0.173
28.23 15.42 29.73 57.78 43.81 42.51 40.84 56.15 39.81 53.22 59.78 54.23 0.065
28.23 15.42 29.73 57.78 50.19 42.51 40.84 56.15 39.81 53.22 40.71 54.23 0.185
28.23 15.42 29.73 45.09 49.14 35.92 40.84 56.15 39.81 58.30 55.76 63.06 0.016
28.23 15.42 29.73 45.09 49.14 43.81 40.84 56.15 39.81 58.30 55.76 59.78 0.028
28.23 15.42 29.73 45.09 49.14 50.19 40.84 56.15 39.81 58.30 55.76 40.71 0.100
28.23 15.42 29.73 45.09 49.14 42.51 40.84 56.15 39.81 58.30 55.76 54.23 0.029
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p-valuesSET 1 SET 2
28.23 15.42 29.73 45.09 35.92 43.81 40.84 56.15 39.81 58.30 63.06 59.78 0.009
28.23 15.42 29.73 45.09 35.92 50.19 40.84 56.15 39.81 58.30 63.06 40.71 0.040
28.23 15.42 29.73 45.09 35.92 42.51 40.84 56.15 39.81 58.30 63.06 54.23 0.009
28.23 15.42 29.73 45.09 43.81 50.19 40.84 56.15 39.81 58.30 59.78 40.71 0.065
28.23 15.42 29.73 45.09 43.81 42.51 40.84 56.15 39.81 58.30 59.78 54.23 0.016
28.23 15.42 29.73 45.09 50.19 42.51 40.84 56.15 39.81 58.30 40.71 54.23 0.067
28.23 15.42 29.73 49.14 35.92 43.81 40.84 56.15 39.81 55.76 63.06 59.78 0.014
28.23 15.42 29.73 49.14 35.92 50.19 40.84 56.15 39.81 55.76 63.06 40.71 0.058
28.23 15.42 29.73 49.14 35.92 42.51 40.84 56.15 39.81 55.76 63.06 54.23 0.014
28.23 15.42 29.73 49.14 43.81 50.19 40.84 56.15 39.81 55.76 59.78 40.71 0.091
28.23 15.42 29.73 49.14 43.81 42.51 40.84 56.15 39.81 55.76 59.78 54.23 0.025
28.23 15.42 29.73 49.14 50.19 42.51 40.84 56.15 39.81 55.76 40.71 54.23 0.095
28.23 15.42 29.73 35.92 43.81 50.19 40.84 56.15 39.81 63.06 59.78 40.71 0.036
28.23 15.42 29.73 35.92 43.81 42.51 40.84 56.15 39.81 63.06 59.78 54.23 0.007
28.23 15.42 29.73 35.92 50.19 42.51 40.84 56.15 39.81 63.06 40.71 54.23 0.036
28.23 15.42 29.73 43.81 50.19 42.51 40.84 56.15 39.81 59.78 40.71 54.23 0.060
28.23 15.42 38.43 24.75 28.26 37.38 40.84 56.15 41.50 47.51 49.23 46.95 0.001
28.23 15.42 38.43 24.75 28.26 38.13 40.84 56.15 41.50 47.51 49.23 51.50 0.001
28.23 15.42 38.43 24.75 28.26 52.11 40.84 56.15 41.50 47.51 49.23 55.94 0.014
28.23 15.42 38.43 24.75 28.26 57.78 40.84 56.15 41.50 47.51 49.23 53.22 0.033
28.23 15.42 38.43 24.75 28.26 45.09 40.84 56.15 41.50 47.51 49.23 58.30 0.005
28.23 15.42 38.43 24.75 28.26 49.14 40.84 56.15 41.50 47.51 49.23 55.76 0.009
28.23 15.42 38.43 24.75 28.26 35.92 40.84 56.15 41.50 47.51 49.23 63.06 0.001
28.23 15.42 38.43 24.75 28.26 43.81 40.84 56.15 41.50 47.51 49.23 59.78 0.004
28.23 15.42 38.43 24.75 28.26 50.19 40.84 56.15 41.50 47.51 49.23 40.71 0.021
28.23 15.42 38.43 24.75 28.26 42.51 40.84 56.15 41.50 47.51 49.23 54.23 0.003
28.23 15.42 38.43 24.75 37.38 38.13 40.84 56.15 41.50 47.51 46.95 51.50 0.004
28.23 15.42 38.43 24.75 37.38 52.11 40.84 56.15 41.50 47.51 46.95 55.94 0.025
28.23 15.42 38.43 24.75 37.38 57.78 40.84 56.15 41.50 47.51 46.95 53.22 0.055
28.23 15.42 38.43 24.75 37.38 45.09 40.84 56.15 41.50 47.51 46.95 58.30 0.010
28.23 15.42 38.43 24.75 37.38 49.14 40.84 56.15 41.50 47.51 46.95 55.76 0.017
28.23 15.42 38.43 24.75 37.38 35.92 40.84 56.15 41.50 47.51 46.95 63.06 0.004
28.23 15.42 38.43 24.75 37.38 43.81 40.84 56.15 41.50 47.51 46.95 59.78 0.008
28.23 15.42 38.43 24.75 37.38 50.19 40.84 56.15 41.50 47.51 46.95 40.71 0.038
28.23 15.42 38.43 24.75 37.38 42.51 40.84 56.15 41.50 47.51 46.95 54.23 0.007
28.23 15.42 38.43 24.75 38.13 52.11 40.84 56.15 41.50 47.51 51.50 55.94 0.022
28.23 15.42 38.43 24.75 38.13 57.78 40.84 56.15 41.50 47.51 51.50 53.22 0.047
28.23 15.42 38.43 24.75 38.13 45.09 40.84 56.15 41.50 47.51 51.50 58.30 0.008
28.23 15.42 38.43 24.75 38.13 49.14 40.84 56.15 41.50 47.51 51.50 55.76 0.015
28.23 15.42 38.43 24.75 38.13 35.92 40.84 56.15 41.50 47.51 51.50 63.06 0.003
28.23 15.42 38.43 24.75 38.13 43.81 40.84 56.15 41.50 47.51 51.50 59.78 0.007
28.23 15.42 38.43 24.75 38.13 50.19 40.84 56.15 41.50 47.51 51.50 40.71 0.034
28.23 15.42 38.43 24.75 38.13 42.51 40.84 56.15 41.50 47.51 51.50 54.23 0.006
28.23 15.42 38.43 24.75 52.11 57.78 40.84 56.15 41.50 47.51 55.94 53.22 0.103
28.23 15.42 38.43 24.75 52.11 45.09 40.84 56.15 41.50 47.51 55.94 58.30 0.032
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p-valuesSET 1 SET 2
28.23 15.42 38.43 24.75 52.11 49.14 40.84 56.15 41.50 47.51 55.94 55.76 0.047
28.23 15.42 38.43 24.75 52.11 35.92 40.84 56.15 41.50 47.51 55.94 63.06 0.016
28.23 15.42 38.43 24.75 52.11 43.81 40.84 56.15 41.50 47.51 55.94 59.78 0.028
28.23 15.42 38.43 24.75 52.11 50.19 40.84 56.15 41.50 47.51 55.94 40.71 0.097
28.23 15.42 38.43 24.75 52.11 42.51 40.84 56.15 41.50 47.51 55.94 54.23 0.028
28.23 15.42 38.43 24.75 57.78 45.09 40.84 56.15 41.50 47.51 53.22 58.30 0.061
28.23 15.42 38.43 24.75 57.78 49.14 40.84 56.15 41.50 47.51 53.22 55.76 0.085
28.23 15.42 38.43 24.75 57.78 35.92 40.84 56.15 41.50 47.51 53.22 63.06 0.034
28.23 15.42 38.43 24.75 57.78 43.81 40.84 56.15 41.50 47.51 53.22 59.78 0.055
28.23 15.42 38.43 24.75 57.78 50.19 40.84 56.15 41.50 47.51 53.22 40.71 0.158
28.23 15.42 38.43 24.75 57.78 42.51 40.84 56.15 41.50 47.51 53.22 54.23 0.057
28.23 15.42 38.43 24.75 45.09 49.14 40.84 56.15 41.50 47.51 58.30 55.76 0.023
28.23 15.42 38.43 24.75 45.09 35.92 40.84 56.15 41.50 47.51 58.30 63.06 0.006
28.23 15.42 38.43 24.75 45.09 43.81 40.84 56.15 41.50 47.51 58.30 59.78 0.012
28.23 15.42 38.43 24.75 45.09 50.19 40.84 56.15 41.50 47.51 58.30 40.71 0.053
28.23 15.42 38.43 24.75 45.09 42.51 40.84 56.15 41.50 47.51 58.30 54.23 0.012
28.23 15.42 38.43 24.75 49.14 35.92 40.84 56.15 41.50 47.51 55.76 63.06 0.011
28.23 15.42 38.43 24.75 49.14 43.81 40.84 56.15 41.50 47.51 55.76 59.78 0.020
28.23 15.42 38.43 24.75 49.14 50.19 40.84 56.15 41.50 47.51 55.76 40.71 0.076
28.23 15.42 38.43 24.75 49.14 42.51 40.84 56.15 41.50 47.51 55.76 54.23 0.020
28.23 15.42 38.43 24.75 35.92 43.81 40.84 56.15 41.50 47.51 63.06 59.78 0.005
28.23 15.42 38.43 24.75 35.92 50.19 40.84 56.15 41.50 47.51 63.06 40.71 0.027
28.23 15.42 38.43 24.75 35.92 42.51 40.84 56.15 41.50 47.51 63.06 54.23 0.005
28.23 15.42 38.43 24.75 43.81 50.19 40.84 56.15 41.50 47.51 59.78 40.71 0.047
28.23 15.42 38.43 24.75 43.81 42.51 40.84 56.15 41.50 47.51 59.78 54.23 0.010
28.23 15.42 38.43 24.75 50.19 42.51 40.84 56.15 41.50 47.51 40.71 54.23 0.045
28.23 15.42 38.43 28.26 37.38 38.13 40.84 56.15 41.50 49.23 46.95 51.50 0.003
28.23 15.42 38.43 28.26 37.38 52.11 40.84 56.15 41.50 49.23 46.95 55.94 0.025
28.23 15.42 38.43 28.26 37.38 57.78 40.84 56.15 41.50 49.23 46.95 53.22 0.055
28.23 15.42 38.43 28.26 37.38 45.09 40.84 56.15 41.50 49.23 46.95 58.30 0.009
28.23 15.42 38.43 28.26 37.38 49.14 40.84 56.15 41.50 49.23 46.95 55.76 0.017
28.23 15.42 38.43 28.26 37.38 35.92 40.84 56.15 41.50 49.23 46.95 63.06 0.003
28.23 15.42 38.43 28.26 37.38 43.81 40.84 56.15 41.50 49.23 46.95 59.78 0.008
28.23 15.42 38.43 28.26 37.38 50.19 40.84 56.15 41.50 49.23 46.95 40.71 0.039
28.23 15.42 38.43 28.26 37.38 42.51 40.84 56.15 41.50 49.23 46.95 54.23 0.006
28.23 15.42 38.43 28.26 38.13 52.11 40.84 56.15 41.50 49.23 51.50 55.94 0.021
28.23 15.42 38.43 28.26 38.13 57.78 40.84 56.15 41.50 49.23 51.50 53.22 0.047
28.23 15.42 38.43 28.26 38.13 45.09 40.84 56.15 41.50 49.23 51.50 58.30 0.008
28.23 15.42 38.43 28.26 38.13 49.14 40.84 56.15 41.50 49.23 51.50 55.76 0.014
28.23 15.42 38.43 28.26 38.13 35.92 40.84 56.15 41.50 49.23 51.50 63.06 0.003
28.23 15.42 38.43 28.26 38.13 43.81 40.84 56.15 41.50 49.23 51.50 59.78 0.007
28.23 15.42 38.43 28.26 38.13 50.19 40.84 56.15 41.50 49.23 51.50 40.71 0.035
28.23 15.42 38.43 28.26 38.13 42.51 40.84 56.15 41.50 49.23 51.50 54.23 0.005
28.23 15.42 38.43 28.26 52.11 57.78 40.84 56.15 41.50 49.23 55.94 53.22 0.103
28.23 15.42 38.43 28.26 52.11 45.09 40.84 56.15 41.50 49.23 55.94 58.30 0.031
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p-valuesSET 1 SET 2
28.23 15.42 38.43 28.26 52.11 49.14 40.84 56.15 41.50 49.23 55.94 55.76 0.046
28.23 15.42 38.43 28.26 52.11 35.92 40.84 56.15 41.50 49.23 55.94 63.06 0.015
28.23 15.42 38.43 28.26 52.11 43.81 40.84 56.15 41.50 49.23 55.94 59.78 0.027
28.23 15.42 38.43 28.26 52.11 50.19 40.84 56.15 41.50 49.23 55.94 40.71 0.098
28.23 15.42 38.43 28.26 52.11 42.51 40.84 56.15 41.50 49.23 55.94 54.23 0.027
28.23 15.42 38.43 28.26 57.78 45.09 40.84 56.15 41.50 49.23 53.22 58.30 0.061
28.23 15.42 38.43 28.26 57.78 49.14 40.84 56.15 41.50 49.23 53.22 55.76 0.084
28.23 15.42 38.43 28.26 57.78 35.92 40.84 56.15 41.50 49.23 53.22 63.06 0.034
28.23 15.42 38.43 28.26 57.78 43.81 40.84 56.15 41.50 49.23 53.22 59.78 0.054
28.23 15.42 38.43 28.26 57.78 50.19 40.84 56.15 41.50 49.23 53.22 40.71 0.161
28.23 15.42 38.43 28.26 57.78 42.51 40.84 56.15 41.50 49.23 53.22 54.23 0.056
28.23 15.42 38.43 28.26 45.09 49.14 40.84 56.15 41.50 49.23 58.30 55.76 0.022
28.23 15.42 38.43 28.26 45.09 35.92 40.84 56.15 41.50 49.23 58.30 63.06 0.006
28.23 15.42 38.43 28.26 45.09 43.81 40.84 56.15 41.50 49.23 58.30 59.78 0.012
28.23 15.42 38.43 28.26 45.09 50.19 40.84 56.15 41.50 49.23 58.30 40.71 0.053
28.23 15.42 38.43 28.26 45.09 42.51 40.84 56.15 41.50 49.23 58.30 54.23 0.011
28.23 15.42 38.43 28.26 49.14 35.92 40.84 56.15 41.50 49.23 55.76 63.06 0.010
28.23 15.42 38.43 28.26 49.14 43.81 40.84 56.15 41.50 49.23 55.76 59.78 0.019
28.23 15.42 38.43 28.26 49.14 50.19 40.84 56.15 41.50 49.23 55.76 40.71 0.077
28.23 15.42 38.43 28.26 49.14 42.51 40.84 56.15 41.50 49.23 55.76 54.23 0.019
28.23 15.42 38.43 28.26 35.92 43.81 40.84 56.15 41.50 49.23 63.06 59.78 0.005
28.23 15.42 38.43 28.26 35.92 50.19 40.84 56.15 41.50 49.23 63.06 40.71 0.027
28.23 15.42 38.43 28.26 35.92 42.51 40.84 56.15 41.50 49.23 63.06 54.23 0.004
28.23 15.42 38.43 28.26 43.81 50.19 40.84 56.15 41.50 49.23 59.78 40.71 0.047
28.23 15.42 38.43 28.26 43.81 42.51 40.84 56.15 41.50 49.23 59.78 54.23 0.009
28.23 15.42 38.43 28.26 50.19 42.51 40.84 56.15 41.50 49.23 40.71 54.23 0.046
28.23 15.42 38.43 37.38 38.13 52.11 40.84 56.15 41.50 46.95 51.50 55.94 0.036
28.23 15.42 38.43 37.38 38.13 57.78 40.84 56.15 41.50 46.95 51.50 53.22 0.074
28.23 15.42 38.43 37.38 38.13 45.09 40.84 56.15 41.50 46.95 51.50 58.30 0.015
28.23 15.42 38.43 37.38 38.13 49.14 40.84 56.15 41.50 46.95 51.50 55.76 0.025
28.23 15.42 38.43 37.38 38.13 35.92 40.84 56.15 41.50 46.95 51.50 63.06 0.006
28.23 15.42 38.43 37.38 38.13 43.81 40.84 56.15 41.50 46.95 51.50 59.78 0.013
28.23 15.42 38.43 37.38 38.13 50.19 40.84 56.15 41.50 46.95 51.50 40.71 0.059
28.23 15.42 38.43 37.38 38.13 42.51 40.84 56.15 41.50 46.95 51.50 54.23 0.011
28.23 15.42 38.43 37.38 52.11 57.78 40.84 56.15 41.50 46.95 55.94 53.22 0.148
28.23 15.42 38.43 37.38 52.11 45.09 40.84 56.15 41.50 46.95 55.94 58.30 0.049
28.23 15.42 38.43 37.38 52.11 49.14 40.84 56.15 41.50 46.95 55.94 55.76 0.071
28.23 15.42 38.43 37.38 52.11 35.92 40.84 56.15 41.50 46.95 55.94 63.06 0.026
28.23 15.42 38.43 37.38 52.11 43.81 40.84 56.15 41.50 46.95 55.94 59.78 0.043
28.23 15.42 38.43 37.38 52.11 50.19 40.84 56.15 41.50 46.95 55.94 40.71 0.146
28.23 15.42 38.43 37.38 52.11 42.51 40.84 56.15 41.50 46.95 55.94 54.23 0.044
28.23 15.42 38.43 37.38 57.78 45.09 40.84 56.15 41.50 46.95 53.22 58.30 0.091
28.23 15.42 38.43 37.38 57.78 49.14 40.84 56.15 41.50 46.95 53.22 55.76 0.123
28.23 15.42 38.43 37.38 57.78 35.92 40.84 56.15 41.50 46.95 53.22 63.06 0.052
28.23 15.42 38.43 37.38 57.78 43.81 40.84 56.15 41.50 46.95 53.22 59.78 0.082
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28.23 15.42 38.43 37.38 57.78 50.19 40.84 56.15 41.50 46.95 53.22 40.71 0.230
28.23 15.42 38.43 37.38 57.78 42.51 40.84 56.15 41.50 46.95 53.22 54.23 0.086
28.23 15.42 38.43 37.38 45.09 49.14 40.84 56.15 41.50 46.95 58.30 55.76 0.036
28.23 15.42 38.43 37.38 45.09 35.92 40.84 56.15 41.50 46.95 58.30 63.06 0.011
28.23 15.42 38.43 37.38 45.09 43.81 40.84 56.15 41.50 46.95 58.30 59.78 0.020
28.23 15.42 38.43 37.38 45.09 50.19 40.84 56.15 41.50 46.95 58.30 40.71 0.083
28.23 15.42 38.43 37.38 45.09 42.51 40.84 56.15 41.50 46.95 58.30 54.23 0.020
28.23 15.42 38.43 37.38 49.14 35.92 40.84 56.15 41.50 46.95 55.76 63.06 0.018
28.23 15.42 38.43 37.38 49.14 43.81 40.84 56.15 41.50 46.95 55.76 59.78 0.032
28.23 15.42 38.43 37.38 49.14 50.19 40.84 56.15 41.50 46.95 55.76 40.71 0.118
28.23 15.42 38.43 37.38 49.14 42.51 40.84 56.15 41.50 46.95 55.76 54.23 0.032
28.23 15.42 38.43 37.38 35.92 43.81 40.84 56.15 41.50 46.95 63.06 59.78 0.009
28.23 15.42 38.43 37.38 35.92 50.19 40.84 56.15 41.50 46.95 63.06 40.71 0.045
28.23 15.42 38.43 37.38 35.92 42.51 40.84 56.15 41.50 46.95 63.06 54.23 0.009
28.23 15.42 38.43 37.38 43.81 50.19 40.84 56.15 41.50 46.95 59.78 40.71 0.075
28.23 15.42 38.43 37.38 43.81 42.51 40.84 56.15 41.50 46.95 59.78 54.23 0.017
28.23 15.42 38.43 37.38 50.19 42.51 40.84 56.15 41.50 46.95 40.71 54.23 0.074
28.23 15.42 38.43 38.13 52.11 57.78 40.84 56.15 41.50 51.50 55.94 53.22 0.127
28.23 15.42 38.43 38.13 52.11 45.09 40.84 56.15 41.50 51.50 55.94 58.30 0.040
28.23 15.42 38.43 38.13 52.11 49.14 40.84 56.15 41.50 51.50 55.94 55.76 0.059
28.23 15.42 38.43 38.13 52.11 35.92 40.84 56.15 41.50 51.50 55.94 63.06 0.021
28.23 15.42 38.43 38.13 52.11 43.81 40.84 56.15 41.50 51.50 55.94 59.78 0.036
28.23 15.42 38.43 38.13 52.11 50.19 40.84 56.15 41.50 51.50 55.94 40.71 0.127
28.23 15.42 38.43 38.13 52.11 42.51 40.84 56.15 41.50 51.50 55.94 54.23 0.037
28.23 15.42 38.43 38.13 57.78 45.09 40.84 56.15 41.50 51.50 53.22 58.30 0.077
28.23 15.42 38.43 38.13 57.78 49.14 40.84 56.15 41.50 51.50 53.22 55.76 0.106
28.23 15.42 38.43 38.13 57.78 35.92 40.84 56.15 41.50 51.50 53.22 63.06 0.044
28.23 15.42 38.43 38.13 57.78 43.81 40.84 56.15 41.50 51.50 53.22 59.78 0.069
28.23 15.42 38.43 38.13 57.78 50.19 40.84 56.15 41.50 51.50 53.22 40.71 0.203
28.23 15.42 38.43 38.13 57.78 42.51 40.84 56.15 41.50 51.50 53.22 54.23 0.073
28.23 15.42 38.43 38.13 45.09 49.14 40.84 56.15 41.50 51.50 58.30 55.76 0.030
28.23 15.42 38.43 38.13 45.09 35.92 40.84 56.15 41.50 51.50 58.30 63.06 0.009
28.23 15.42 38.43 38.13 45.09 43.81 40.84 56.15 41.50 51.50 58.30 59.78 0.016
28.23 15.42 38.43 38.13 45.09 50.19 40.84 56.15 41.50 51.50 58.30 40.71 0.072
28.23 15.42 38.43 38.13 45.09 42.51 40.84 56.15 41.50 51.50 58.30 54.23 0.016
28.23 15.42 38.43 38.13 49.14 35.92 40.84 56.15 41.50 51.50 55.76 63.06 0.015
28.23 15.42 38.43 38.13 49.14 43.81 40.84 56.15 41.50 51.50 55.76 59.78 0.026
28.23 15.42 38.43 38.13 49.14 50.19 40.84 56.15 41.50 51.50 55.76 40.71 0.102
28.23 15.42 38.43 38.13 49.14 42.51 40.84 56.15 41.50 51.50 55.76 54.23 0.026
28.23 15.42 38.43 38.13 35.92 43.81 40.84 56.15 41.50 51.50 63.06 59.78 0.007
28.23 15.42 38.43 38.13 35.92 50.19 40.84 56.15 41.50 51.50 63.06 40.71 0.039
28.23 15.42 38.43 38.13 35.92 42.51 40.84 56.15 41.50 51.50 63.06 54.23 0.007
28.23 15.42 38.43 38.13 43.81 50.19 40.84 56.15 41.50 51.50 59.78 40.71 0.064
28.23 15.42 38.43 38.13 43.81 42.51 40.84 56.15 41.50 51.50 59.78 54.23 0.014
28.23 15.42 38.43 38.13 50.19 42.51 40.84 56.15 41.50 51.50 40.71 54.23 0.064
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